0001382574 false 0001382574 2022-02-15 2022-02-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): February 15, 2022

 

TRxADE HEALTH, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-39199   46-3673928

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2420 Brunello Trace
Lutz, Florida
  33558
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 800-261-0281

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

Common Stock,

$0.00001 Par Value Per Share

  MEDS  

The NASDAQ Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On February 15, 2022, TRxADE HEALTH, INC. (the “Company”, “we” and “our”), entered into a relationship    with Exchange Health, LLC, a technology company providing an online platform for manufacturers and suppliers to sell and purchase pharmaceuticals (“Exchange Health”). SOSRx LLC, a Delaware limited liability company (“SOSRx”), was formed, which is owned 51% by the Company and 49% by Exchange Health.

 

On February 15, 2022, the Company contributed cash to SOSRx in the amount of $325,000, issued a promissory note to SOSRx in the amount of $500,000, which was immediately assigned to Exchange Health (the “Promissory Note”), and agreed to make an earn out payment of up to $400,000, payable, at the Company’s discretion, in cash or common stock of the Company, based on SOSRx achieving certain revenue targets of SOSRx as discussed below (the “Earn Out Payments”); and entered into a Distribution Services Agreement with SOSRx (the “Distribution Agreement”).

 

The Earn Out Payments require the Company to pay (a) $25,000 to Exchange Health if total revenue for SOSRx are over $0.7 million, and $25,000 to Exchange Health if total EBITDA is over $0.5 million, for fiscal year ending 2022; (b) $87,500 to Exchange Health if total revenue for SOSRx is over $3.3 million, and $87,500 to Exchange Health if total EBITDA is over $2.95 million, for fiscal year ending 2023; and (c) $87,500 to Exchange Health if total revenue for SOSRx is over $5.7 million, and $87,500 to Exchange Health if total EBITDA is over $4.9 million, for fiscal year ending 2024, provided that certain amounts will be payable in the event at least 95% of such milestones are met, and such payments will be grossed up or down by up to 5% of such amounts, if such milestone amounts are between 95% and 105% of the required thresholds. At the Company’s option, the Earn Out Payments may be paid in cash or shares of common stock, valued at the then current trading price of the Company’s common stock  . If one year’s milestones are not achieved, no earnout will be payable for that year and those earn out payments will not be eligible to be earned in any other year.

 

Exchange Health contributed certain property, contracts and licenses to SOSRx, having an agreed value of $792,500, in exchange for its 49% membership interest in SOSRx and received a cash payment of $275,000 from SOSRx, LLC  , pursuant to a Member Asset Contribution Agreement (the “Asset Contribution Agreement”), also entered into on February 15, 2022.

 

Promissory Note

 

The Promissory Note, which was immediately assigned to Exchange Health, and represents amounts currently due to Exchange Health, bears interest at the rate of the prime rate, plus 2% per annum (currently 5.25% per annum), with (i) one-third of the principal ($166,666.67) and interest payable after one year (on February 15, 2023) and (ii) the remaining two-thirds of principal payable quarterly over the next two years in eight equal installments of $41,666.67, together with any unpaid accrued interest thereupon, at the end of every full fiscal quarter, beginning, June 20, 2023. The Promissory Note may be prepaid by the Company, at its discretion, in whole or in part at any time, without premium or penalty.

 

Notwithstanding the foregoing, if the Company effectuates a Voluntary Withdrawal (defined below) under the Company Agreement (as discussed below) prior to February 15, 2024 (the “Earn Out Period”), and SOSRx has failed to meet any of the revenue targets required by the Earn Out Payments prior to the expiration of the Earn Out Period, then all remaining amounts of interest and principal not yet due and payable under the Promissory Note shall immediately terminate and all related indebtedness evidenced hereby shall be deemed canceled.

 

 

 

 

Amounts owed under the Promissory Note are secured by the Company’s membership interests in the SOSRx and are a non-recourse obligation of the Company, secured solely by such membership interests.

 

In the event that the Company is delinquent to pay when due (whether at maturity, by reason of acceleration or otherwise) any principal of or interest on the Promissory Note, then if such payment is not made within fifteen days of the due date, then Exchange Health may declare an additional interest fee of 2% of the delinquent amount to be due. If the delinquency is thirty days or more late from the due date, then Exchange Health may declare another additional interest fee of 3%, to make a total of 5%, for the delinquent payment.

 

In the event that we fail to pay when due (whether at maturity, by reason of acceleration or otherwise) any principal of or interest on Promissory Note, then if such payment is not made within sixty days of the due date, then Exchange Health may declare all obligations (including without limitation, outstanding principal and accrued and unpaid interest thereon) under the Promissory Note to be immediately due and payable.

 

SOSRx Operating Agreement

 

The rights of the Company and Exchange Health in connection with SOSRx are set forth in the Operating Agreement of SOSRx (the “Operating Agreement”), effective February 15, 2022. Pursuant to the Operating Agreement, SOSRx is to be managed by a management committee consisting of three members, two of which are nominated by the Company, who currently include Suren Ajjarapu, the Company’s Chief Executive Officer and Chairman and Prashant Patel, the Company’s President and director, and one person nominated by Exchange Health. If either the Company or Exchange Health shall ever hold less than 25% of the membership interests of SOSRx, such entity shall forfeit its management appointment rights, and such appointment rights shall be held by such other member which holds over 50% of the membership interests.

 

The Operating Agreement includes customary transfer restrictions on the SOSRx membership interests, right of first refusal rights upon receipt of a bona fide third party offer for purchase of a member’s membership interest (exercisable first by SOSRx and then the other members), preemptive rights (subject to certain exceptions), tag-along rights, and drag-along rights (applying if any greater than 50% owner desires to transfer their ownership in SOSRx).

 

Any member of SOSRx has the right to effect a voluntary withdrawal from the Company (a “Voluntary Withdrawal”), provided that such member must give ninety days prior written notice to all other members. Any member who effectuates a Voluntary Withdrawal is not permitted to receive the fair value or any value of the member’s membership interest as of the date of the Voluntary Withdrawal, and may instead effect a Voluntary Withdrawal by forfeiture of its membership interests in SOSRx without compensation or consideration; provided however, that if the Company (a) effectuates a Voluntary Withdrawal prior to February 15, 2024, and (b) SOSRx has failed to meet any of the revenue targets required by the Earn Out Payments prior to the date of withdrawal, then all obligations of the Company under the Earn Out Payments and the Promissory Note shall terminate.

 

The Company or its assigns may at any time by written notice to any other member, offer to purchase all (but not less than all) of such other member’s membership interests, which shall be calculated and payable pursuant to a discounted cash flow model. If the buyout is paid to Exchange Health or its successors or assigns, any remaining amounts payable under the Promissory Note become immediately due and payable upon such payment.

 

The Operating Agreement also provides, that without the prior written approval of the unanimous consent of the management committee, a manager or member may not, directly or indirectly, (a) enter into a business relationship with any other person that is materially adverse to the business of SOSRx or an affiliate of SOSRx, or (b) cause any person to reduce or terminate its relationship with SOSRx or any affiliate of SOSRx. The foregoing covenants apply to each member, and each manager during the period in which each manager is a member.

 

 

 

 

Distribution Agreement 

 

On February 15, 2022, SOSRx entered into the Distribution Agreement with Integra Pharma Solutions LLC, the Company’s wholly-owned subsidiary (“Integra”). Pursuant to the Distribution Agreement, Integra appoints each SOSRx member an active account for Manufacturer Non-Control (Schedule 2-5 as classified by the US Drug Enforcement Agency) products bought on the SOSRx platform. The agreement remains in effect until December 31, 2023, and renews there after on a yearly basis until terminated; which agreement can only be terminated by the non-breaching party, upon the breach of the agreement by a party thereto, with a 30 day cure right. Pursuant to the Distribution Agreement, for each calendar quarter (or portion thereof) during the term, SOSRx agreed to pay Integra a fee equal to 2% of the net price of all purchases of products during such period. Integra also agreed to participate in SOSRx’s annual trade show, once established. Integra made certain representations and warranties in the Distribution Services Agreement, and agreed to indemnify SOSRx against certain damages and losses. The Distribution Services Agreement included customary confidentiality obligations  .

 

Asset Contribution Agreement

 

On February 15, 2022, Exchange Health entered into a Member Asset Contribution Agreement with SOSRx, pursuant to which it contributed certain assets and assigned certain contracts, relating to software, manufacturers and members, to SOSRx, in consideration for its 49% membership interest in SOSRx. SOSRx did not assume any of Exchange Health’s liabilities or obligations other than the obligations and commitments of Exchange Health arising under the assumed contracts  .

 

* * * * *

 

The foregoing description of the Operating Agreement, Promissory Note, Distribution Agreement and Asset Contribution Agreement, is only a summary and is not complete, and is qualified in its entirety by reference to the Operating Agreement, Promissory Note, Distribution Agreement and Asset Contribution Agreement, copies of which are attached hereto as Exhibits 3.1, 10.1, 10.2, and 10.3, respectively, to this Current Report on Form 8-K and incorporated into this Item 1.01 in their entirety by reference.

 

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information provided in Item 1.01 of this Current Report on Form 8-K, including as it relates to the Promissory Note and Earnout Payments, is hereby incorporated by reference into this Item 2.03 in its entirety  .

 

Item 3.02 Unregistered Sales of Equity Securities

 

The information set forth under Item 1.01 of this Current Report on Form 8-K relating to the Earn Out Payments is incorporated by reference into this Item 3.02.

 

The offer and sale of the shares of common stock issuable pursuant to the terms of the Earn Out Payments (the “Earn Out Shares”), to the extent issued at the option of the Company when and if due, are intended to be exempt from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “Securities Act”), since the foregoing offer, sales and issuances were/will not involve a public offering, Exchange Health has represented that it is an “accredited investor”, and will acquire the securities for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof. The securities were/will be offered without any general solicitation by us or our representatives. The securities offered will not be or have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The securities are subject to transfer restrictions, and the certificates evidencing the securities will contain an appropriate legend stating that such securities have not been registered under the Securities Act and may not be offered or sold absent registration or pursuant to an exemption therefrom.

 

 

 

 

Pursuant to the Operating Agreement, the Earn Out Shares are limited to no more than 19.99% of the total number of shares of common stock outstanding on the date the Operating Agreement was entered into, which totals a maximum of 1,632,474 shares of common stock. As such, a maximum of 1,632,474 shares of common stock may be issued in connection with the Earn Out Shares.

 

Item 7.01 Regulation FD Disclosure.

 

On February 15, 2022, the Company issued a press release relating to the transactions described in Item 1.01, above, a copy of which press release is included herewith as Exhibit 99.1.

 

The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of this Report is not intended to constitute a determination by the Company that the information is material or that the dissemination of the information is required by Regulation FD.

 

The press release attached hereto as Exhibit 99.1 contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words such as “may,” “should,” “expect,” “anticipate,” “believe,” “estimate,” “intend,” “plan” and other similar expressions. Forward-looking statements are not a guarantee of performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and are beyond our control. These risks and uncertainties should be carefully considered. We caution you not to place undue reliance on the forward-looking statements, which involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied in such statements. Forward-looking statements may include comments as to the Company’s beliefs and expectations as to future financial performance, events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the Company’s control. More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s periodic and current filings with the SEC, including the Form 10-Qs and Form 10-Ks, filed with the SEC and available at www.sec.gov and in the “NASDAQ:MEDS” — “SEC Filings” section of the Company’s website at https://www.investors.trxadegroup.com, and specifically including the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and subsequent periodic reports. Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

 

Item 9.01. Financial Statements and Exhibits.

 

Exhibit

No.

  Description
 3.1*#   Limited Liability Company Agreement of SOSRx LLC effective February 15, 2022
10.1*   Non Recourse Promissory Note in the amount of $500,000, dated February 15, 2022, by TRxADE HEALTH, INC. in favor of Exchange Health, LLC
10.2*#   Distribution Services Agreement dated February 15, 2022, by and between SOSRx LLC and Integra Pharma Solutions LLC
10.3*#   Member Asset Contribution Agreement dated February 15, 2022, between Exchange Health, LLC and SOSRx LLC
99.1**   Press release dated February 15, 2022
104   Inline XBRL for the cover page of this Current Report on Form 8-K

 

* Filed herewith.

** Furnished herewith.

# Certain schedules, exhibits, annexes and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that TRxADE HEALTH, INC. may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  TRxADE HEALTH, INC.
   
Date: February 16, 2022 By: /s/ Suren Ajjarapu
  Name: Suren Ajjarapu
  Title: Chief Executive Officer

 

 

 

 

Exhibit 3.1

 

 

Limited Liability Company Agreement of

SOSRx, LLC

 

 

 1 

 

 

SOSRx, LLC

Limited Liability Company Agreement

 

THIS LIMITED LIABILITY COMPANY AGREEMENT (this “Agreement”) is entered into this 15th day of February, 2022 hereto (“Effective Date”).

 

Explanatory Statement

 

The parties have agreed to form and operate a limited liability company under the Delaware Limited Liability Company Act, 6 Del. C. §18-101 et seq, in accordance with the terms and subject to the conditions set forth in this Agreement.

 

NOW, THEREFORE, for good and valuable consideration, the parties, intending legally to be bound, agree as follows:

 

Section I

Defined Terms

 

The following terms shall have the meanings specified in this Section I. Other terms are defined in the text of this Agreement; and, throughout this Agreement, those terms shall have the meanings respectively ascribed to them.

 

“Act” means the Delaware Limited Liability Company Act, 6 Del.C. § 18-101 et seq., as amended from time to time.

 

 

“Affiliate” means, with respect to any Member, any Person: (i) which owns more than 50% of the voting interests in the Member; or (ii) in which the Member owns more than 50% of the voting interests; or (iii) in which more than 50% of the voting interests are owned by a Person who has a relationship with the Member described in clause (i) or (ii) above.

 

“Agreement” means this Limited Liability Company Agreement, as amended from time to time.

 

“Capital Account” means the account to be maintained by the Company for each Interest Holder in accordance with the following provisions:

 

(i) an Interest Holder’s Capital Account shall be credited with the Interest Holder’s Capital Contributions, the amount of any Company liabilities assumed by the Interest Holder (or which are secured by Company property distributed to the Interest Holder), the Interest Holder’s distributive share of Profit and any item in the nature of income or gain specially allocated to such Interest Holder pursuant to the provisions of Section IV; and

 

(ii) an Interest Holder’s Capital Account shall be debited with the amount of money and the fair market value of any Company property distributed to the Interest Holder, the amount of any liabilities of the Interest Holder assumed by the Company (or which are secured by property contributed by the Interest Holder to the Company), the Interest Holder’s distributive share of Loss, and any item in the nature of expenses or losses specially allocated to the Interest Holder pursuant to the provisions of Section IV.

 

 2 

 

 

If any Interest is transferred pursuant to the terms of this Agreement, the transferee shall succeed to the Capital Account of the transferor to the extent the Capital Account is attributable to the transferred Interest.

 

“Capital Contribution” means the total amount of cash and the fair market value of any other assets contributed or deemed contributed under the Code to the Company by a Member, net of liabilities assumed or to which the assets are subject.

 

“Capital Proceeds” means the gross receipts received by the Company from a Capital Transaction.

 

“Capital Transaction” means any transaction other than in the ordinary course of business which results in the Company’s receipt of cash or other consideration other than Capital Contributions, including, without limitation, proceeds of sales or exchanges or other dispositions of property other than in the ordinary course of business, financing, refinancing, condemnations, recoveries of damage awards and insurance proceeds.

 

“Cash Flow” means all cash funds derived from operations of the Company (including interest received on reserves), without reduction for any non-cash charges, but less cash funds used to pay current operating expenses and to pay or establish reasonable reserves for future expenses, debt payments, capital improvements, and replacements as determined by the Management Committee. Cash Flow shall not include Capital Proceeds but shall be increased by the reduction of any reserve previously established.

 

“Certificate of Formation” means the Certificate of Formation of the Company filed with the Office of the Delaware Secretary of State in accordance with the Act.

 

“Code” means the Internal Revenue Code of 1986, as amended, or any corresponding provision of any succeeding law.

 

“Company” means the limited liability company formed in accordance with this Agreement.

 

“Company Assets” means the operating assets of the company, including but not limited to those assets listed in the Asset Contribution Agreement, attached hereto as Exhibit E.

 

Exchange Health” means Exchange Health, LLC, a Michigan limited liability company.

 

“Interest” means an Interest Holder’s share of the Profits and Losses of, and the right to receive distributions from the Company.

 

 3 

 

 

“Interest Holder” means any Person who holds an Interest, whether as a Member or an assignee of a Member who has not been admitted to the Company as a Member.

 

“Involuntary Withdrawal” means, with respect to any Member, the occurrence of any of the following events:

 

(i) the Member makes an assignment for the benefit of creditors;

 

(ii) the Member files a voluntary petition of bankruptcy;

 

(iii) the Member is adjudged bankrupt or insolvent or there is entered against the Member an order for relief in any bankruptcy or insolvency proceeding;

 

(iv) the Member files a petition or answer seeking for the Member any reorganization, arrangement, composition, readjustment, liquidation, dissolution, or similar relief under any statute, law, or regulation;

 

(v) the Member seeks, consents to, or acquiesces in the appointment of a trustee, receiver, or liquidator of the Member or of all or any substantial part of the Member’s properties;

 

(vi) the Member files an answer or other pleading admitting or failing to contest the material allegations of a petition filed against the Member in any proceeding described in Subsections (i) through (v);

 

(vii) within one hundred twenty days (120) days of any proceeding against the Member seeking reorganization, arrangement, composition, readjustment, liquidation, dissolution, or similar relief under any statute, law, or regulation if the proceeding has not been dismissed, or within ninety (90) days after the appointment of a trustee, receiver, or liquidator for the Member or all or any substantial part of the Member’s properties without the Member’s agreement or acquiescence, which appointment is not vacated or stayed, or if the appointment is stayed, for ninety (90) days after the expiration of the stay which period the appointment is not vacated;

 

(viii) if the Member is an individual, the Member’s death or adjudication by a court of competent jurisdiction as incompetent to manage the Member’s person or property;

 

(ix) if the Member is acting as a Member by virtue of being a trustee of a trust, the termination of the trust;

 

(x) if the Member is a partnership or another limited liability company, the dissolution and commencement of winding up of the partnership or limited liability company;

 

(xi) if the Member is a corporation, the dissolution of the corporation or the revocation of its charter; or

 

(xii) if the Member is an estate, the distribution by the fiduciary of the estate’s entire interest in the limited liability company.

 

 4 

 

 

“Management Committee” means the Management Committee described and constituted pursuant to Section 5.1 of this Agreement.

 

“Member” means each Person signing this Agreement and any Person who subsequently is admitted as a member of the Company in accordance with the terms of this Agreement.

 

“Membership Rights” means all of the rights of a Member in the Company, including a Member’s: (i) Interest; (ii) right to inspect the Company’s books and records; and (iii) right to participate in the management of and vote on matters coming before the Company.

 

“Negative Capital Account” means a Capital Account with a balance of less than zero.

 

“Percentage” means, as to a Member, the percentage set forth after the Member’s name on Exhibit A of this Agreement, as amended from time to time, and as to an Interest Holder who is not a Member, the Percentage of the Member’s Interest that has been acquired by such Interest Holder, to the extent the Interest Holder has succeeded to that Member’s Interest.

 

“Person” means and includes any individual, corporation, partnership, association, limited liability company, trust, estate, or other entity.

 

“Positive Capital Account” means a Capital Account with a balance greater than zero.

 

“Profit” and “Loss” means, for each taxable year of the Company (or other period for which Profit or Loss must be computed) the Company’s taxable income or loss determined in accordance with applicable partnership tax rules.

 

“Regulation” means the income tax regulations, including any temporary regulations, from time to time promulgated under the Code.

 

Supermajority Interest” shall mean the affirmative vote of Members holding at least 66 2/3% of the outstanding Interests.

“Transfer” means, when used as a noun, any voluntary sale, hypothecation, pledge, assignment, attachment, or other transfer, and, when used as a verb, means, voluntarily to sell, hypothecate, pledge, assign, or otherwise transfer.

 

Trxade Health” Means TRxADE HEALTH, INC., a Delaware corporation.

 

Value” means, with respect to any asset, the asset’s adjusted basis for federal income tax purposes, except as follows:

(a) the initial Value of any asset (other than money) contributed by a Member to the Company shall be the gross fair market value of such asset (i) as set forth on a schedule hereto or (ii) if such asset is not listed on such schedule, as reasonably determined by the Management Committee;

 

 5 

 

 

(b) the Values of all Company Assets shall be adjusted to equal their respective gross fair market values as reasonably determined by the Manager as of the following times: (i) the acquisition of an additional interest in the Company by any new or existing Member in exchange for more than a de minimis Capital Contribution; (ii) the distribution by the Company to a Member of more than a de minimis amount of property in respect of an interest in the Company; (iii) the liquidation of the Company within the meaning of Section 1.704-1(b)(2)(ii)(g) of the Treasury Regulations; or (iv) any other instance in which such adjustment is permitted under Treasury Regulations Section 1.704-1(b)(2)(iv) (e.g., in connection with the grant of an interest in the Company (other than a de minimis interest) as consideration for the provision of services to or for the benefit of the Company); provided, however, that any adjustment pursuant to clauses (i), (ii), (iii), and (iv) above shall be made only if the Management Committee in reasonable good faith determines that such adjustments are necessary or appropriate to reflect the relative economic interests of the Members in the Company; and

 

(c) the Value of any Company asset distributed to any Member shall be the gross fair market value of such asset on the date of distribution, as determined in reasonable good faith by the Management Committee.

 

If the Value of an asset has been determined or adjusted pursuant to clause (a) or (b), such Value shall thereafter be adjusted by the Depreciation taken into account with respect to such asset.

 

“Voluntary Withdrawal” means a Member’s dissociation with the Company by means other than by a Transfer in compliance with this Agreement or an Involuntary Withdrawal.

 

Section II

Formation and Name: Office; Purpose; Term

 

2.1. Organization. The parties hereby organize a limited liability company pursuant to the Act and the provisions of this Agreement and, for that purpose, the Management Committee shall cause a Certificate of Formation to be executed and filed with the Office of the Secretary of State of the State of Delaware.

 

2.2. Name of the Company. The name of the Company shall be “SOSRx, LLC.” The Company may do business under that name and under any other name or names upon which the Management Committee selects in its sole discretion. If the Company does business under a name other than that set forth in its Certificate of Formation, then the Company shall file a fictitious name certificate or any other documents as required by applicable law.

 

2.3. Purpose. The Company is organized conduct it distribution business and otherwise deal in and with the Company Assets and to do any and all things necessary, convenient, or incidental to that purpose (the “Business”).

 

2.4. Term. The term of the Company shall begin upon the acceptance of the Certificate of Formation by the office of the Secretary of State of the State of Delaware and shall continue in existence in perpetuity, unless its existence is sooner terminated pursuant to Section VII of this Agreement.

 

 6 

 

 

2.5. Registered Office. The registered office of the Company in the State of Delaware shall be located at 850 New Burton Road, Suite 201, Dover, DE 19904 or at any other place within the State of Delaware which the Management Committee shall select. The principal office of the Company shall be at any other location which the Management Committee shall select.

 

2.6. Registered Agent. The name of the Company’s registered agent in the State of Delaware shall be COGENCY GLOBAL INC.

 

2.7. Members. The name, present mailing address, taxpayer identification number, and Percentage of each Member are set forth on Exhibit A attached hereto.

 

Section III

Members; Capital; Capital Accounts

 

3.1. Initial Contributions. Upon the execution of this Agreement:

 

3.1.1 Trxade Health shall (a) contribute cash to the Company in the amount of $325,500; (b) ) contribute a promissory note for $500,000, bearing interest at prime plus 2%, with (i) one-third of the principal and interest payable after one year and (ii) the remaining two-thirds of principal and interest payable quarterly over the next two years in the form attached here as Exhibit B (the “Note”); (c) make an earnout payment of up to $400,000, payable, at Trxade Health’s discretion, in cash or Common Stock of Trxade Health at the then current trading price with the total amount based achievement of certain revenue targets of the Company achievable over two years and further described on Exhibit C attached hereto (the “Earn Out Payment”); and (d) enter into a Distribution Agreement with the Company, in the form attached hereto as Exhibit D (the “Distribution Agreement”), having the agreed value listed in the Capital Account.

 

3.1.2 Exchange Health shall contribute to the Company that property and those contracts and licenses described in the Asset Contribution Agreement, attached hereto as Exhibit E (the “ACA”) having the agreed value listed in the Capital Account, in exchange for: its Interest set for on Exhibit A, Exchange Health’s assumption of the Note and the Earn Out Payments, and the Company’s payment to Exchange Health of $275,000, as further set forth in the ACA.

 

3.1.3 Notwithstanding anything herein to the contrary, the maximum number of shares of Trxade Health Common Stock to be issued in connection with the Earn Out Payment or otherwise hereunder shall not (i) exceed 19.9% of the outstanding shares of Trxade Health Common Stock immediately prior to the adoption of this Agreement, (ii) exceed 19.9% of the combined voting power of the then outstanding voting securities of Trxade Health immediately prior to the adoption of this Agreement, in each of subsections (i) and (ii) before the issuance of the Trxade Health Common Stock hereunder in connection with the earnout, or (iii) otherwise exceed such number of shares of Trxade Health Common Stock that would violate applicable listing rules of the NASDAQ Stock Market in the event the Trxade Health stockholders do not approve the issuance of the Trxade Health Common Stock hereunder (the “Share Cap”). In the event the number of shares of Trxade Health Common Stock to be issued hereunder, whether as part of the Earn Out Payment or otherwise, exceeds the Share Cap, then Trxade Health shall instead be required to pay cash in connection with such Earn Out Payment or portion thereof which would exceed the Share Cap, or it shall otherwise first obtain the approval of the Trxade Health stockholders under applicable rules and requirements of the NASDAQ Capital Market prior to issuing such shares of Trxade Health Common Stock.

 

 7 

 

 

3.2. Additional Capital Contributions.

 

3.2.1. If the Management Committee at any time or from time to time determines that the Company requires additional Capital Contributions, then the Management Committee shall give notice to each Member of (i) the total amount of additional Capital Contributions required, (ii) the reason the additional Capital Contribution is required, (iii) each Member’s proportionate share of the total additional Capital Contribution (determined in accordance with this Section), and (iv) the date each Member’s additional Capital Contribution is due and payable, which date shall be thirty (30) days after the notice has been given. A Member’s proportionate share of the total additional Capital Contribution shall be equal to the product obtained by multiplying the Member’s Percentage and the total additional Capital Contribution required. A Member’s proportionate share shall be payable in cash or by certified check or by wire transfer.

 

3.2.2. Except as provided in Section 3.2.1, no Member shall be required to contribute any additional capital to the Company, and no Member shall have any personal liability for any obligation of the Company or any other Member except to the extent provided in Section 3.2.3.

 

3.2.3. If a Member fails to pay when due all or any portion of any Capital Contribution, the Management Committee shall request the non-defaulting Members to pay the unpaid amount of the defaulting Member’s Capital Contribution (the “Unpaid Contribution”). To the extent the Unpaid Contribution is contributed by any other Member, the defaulting Member’s Percentage shall be reduced and the Percentage of each Member who makes up the Unpaid Contribution shall be increased, so that each Member’s Percentage is equal to a fraction, the numerator of which is that Member’s total Capital Contribution and the denominator of which is the total Capital Contributions of all Members. The Management Committee shall amend Exhibit A accordingly. This remedy is in addition to any other remedies allowed by law or by this Agreement.

 

3.3. No Interest on Capital Contributions. Interest Holders shall not be paid interest on their Capital Contributions.

 

3.4. Return of Capital Contributions. Except as otherwise provided in this Agreement, no Interest Holder shall have the right to the return of any Capital Contribution.

 

3.5. Capital Accounts. A separate Capital Account shall be maintained for each Interest Holder.

 

3.6. Loans. Any Member or the Management Committee may, at any time, make or cause a loan to be made to the Company in any amount and on those terms upon which the Company and the Member and the Management Committee shall agree.

 

 8 

 

 

Section IV

Profit, Loss, and Distributions

 

4.1. Distributions of Cash Flow and Allocations of Profit or Loss Other than from Capital Transactions.

 

4.1.1. Profit or Loss Other Than from a Capital Transaction. After giving effect to the special allocations set forth in Section 4.3, for any taxable year of the Company, Profit or Loss (other than Profit or Loss resulting from a Capital Transaction, which Profit or Loss shall be allocated in accordance with the provisions of Sections 4.2.1 and 4.2.2) shall be allocated to the Interest Holders such that the Capital Account balance of each Member, immediately after making such allocation, is, as nearly as possible, equal (proportionately) to the distributions that would be made to such Member pursuant to Section 4.2, if the Company’s assets sold for cash equal to their Values, all Company liabilities were satisfied (limited with respect to each nonrecourse liability to the Values of the assets securing such liability), and the net assets of the Company were distributed in accordance with Section 4.2 to the Members immediately after making such allocation; provided, however, that the Net Losses allocated to a Member shall not exceed the maximum amount of Net Losses that can be so allocated without causing such Member to have a negative Capital Account balance at the end of any Fiscal Year.

 

4.1.2. Cash Flow. Subject to applicable law and any limitations contained elsewhere in this Agreement, Cash Flow for each taxable quarter and year of the Company shall be distributed to the Interest Holders in proportion to their Percentages no later than sixty (60) days after each fiscal quarter and seventy-five (75) days after the end of the taxable year.

 

4.2. Distribution of Capital Proceeds and Allocation of Profit or Loss from Capital Transactions.

 

4.2.1. Profit. After giving effect to the special allocations set forth in Section 4.3, Profit from a Capital Transaction shall be allocated as follows:

 

4.2.1.1. If one or more Interest Holders has a Negative Capital Account, to those Interest Holders, in proportion to their Negative Capital Accounts, until all of those Negative Capital Accounts have been increased to zero.

 

4.2.1.2. Any Profit not allocated pursuant to Section 4.2.1.1 shall be allocated to the Interest Holders in proportion to, and to the extent of, the amounts distributable to them pursuant to Sections 4.2.3.4.1 and 4.2.3.4.3.

 

4.2.1.3. Any Profit in excess of the foregoing allocations shall be allocated to the Interest Holders in proportion to their Percentages.

 

 9 

 

 

4.2.2. Loss. After giving effect to the special allocations set forth in Section 4.3, Loss from a Capital Transaction shall be allocated as follows:

 

4.2.2.1. If one or more Interest Holders has a Positive Capital Account, to those Interest Holders, in proportion to their Positive Capital Accounts, until all Positive Capital Accounts have been reduced to zero.

 

4.2.2.2. Any Loss not allocated to reduce Positive Capital Accounts to zero pursuant to Section 4.2.2.1 shall be allocated to the Interest Holders in proportion to their Percentages.

 

4.2.3. Capital Proceeds. Subject to applicable law and any limitations contained elsewhere in this Agreement, Capital Proceeds shall be distributed and applied by the Company in the following order and priority:

 

4.2.3.1. to the payment of all expenses of the Company incident to the Capital Transaction; then

 

4.2.3.2. to the payment of debts and liabilities of the Company then due and outstanding (including all debts due to any Interest Holder); then

 

4.2.3.3. to the establishment of any reserves which the Management Committee deems necessary for current and future liabilities or obligations and business plan of the Company; then

 

4.2.3.4. the balance shall be distributed as follows:

 

4.2.3.4.1. to the Interest Holders in proportion to their Capital Account balances, until their remaining Capital Account balances have been paid in full;

 

4.2.3.4.2. if any Interest Holder has a Positive Capital Account after the distributions made pursuant to Section 4.2.3.4.1 and before any further allocation of Profit pursuant to Section 4.2.1.3, to those Interest Holders in proportion to their Positive Capital Accounts; then

 

4.2.3.4.3. the balance, to the Interest Holders in proportion to their Percentages.

 

4.3. Tax Distributions

 

4.3.1. During each taxable year of the Company, and in any event no later than March 31 of the following taxable year, each Interest Holder who has been allocated net taxable income of the Company for such taxable year shall be entitled to receive a cash distribution (or distributions) equal to his allocable share of such net taxable income multiplied by a percentage equal to the highest rate of tax imposed on individuals for federal and applicable state income tax purposes for such taxable year (without regard to alternative minimum taxes or tax surcharges), (a “Tax Distribution”). The Company may distribute Tax Distributions in quarterly installments on an estimated basis prior to the end of a taxable year.

 

 10 

 

 

4.3.2. Any Tax Distributions shall be deemed to be an advance distribution of amounts otherwise distributable to the Interest Holders pursuant to Section 4.1.2.

 

4.3.3. Notwithstanding the provisions of this Section 4.3, the Management Committee may suspend, withhold and/or cancel any Tax Distributions to the Interest Holders in the event that any such Tax Distribution, in the sole and absolute discretion of the Management Committee, likely would cause the Company to breach any material agreement to which the Company is a party, including without limitation any loan document or promissory note to a primary commercial lender of the Company.

 

4.4. Liquidation and Dissolution.

 

4.4.1. If the Company is liquidated, the assets of the Company shall be distributed to the Interest Holders in accordance with the balances in their respective Capital Accounts, after taking into account the allocations of Profit or Loss pursuant to Sections 4.1 or 4.2, if any, and distributions, if any, of cash or property, if any, pursuant to Sections 4.1 and 4.2.3, and 4.3.

 

4.4.2. No Interest Holder shall be obligated to restore a Negative Capital Account.

 

4.5. General.

 

4.5.1. Except as otherwise provided in this Agreement, the timing and amount of all distributions shall be determined by the Management Committee.

 

4.5.2. The Company Assets may be distributed in kind to the Interest Holders, and those assets shall be valued on the basis of their fair market value. Unless the Members otherwise agree, the fair market value of the assets shall be determined by an independent appraiser who shall be selected by the Management Committee. The Profit or Loss for each unsold asset shall be determined as if the asset had been sold at its fair market value, and the Profit or Loss shall be allocated as provided in Section 4.2 and shall be properly credited or charged to the Capital Accounts of the Interest Holders prior to the distribution of the assets in liquidation pursuant to Section 4.4.

 

4.5.3. All Profit and Loss shall be allocated, and all distributions shall be made to the Persons shown on the records of the Company to have been Interest Holders as of the last day of the taxable year for which the allocation or distribution is to be made. Notwithstanding the foregoing, unless the Company’s taxable year is separated into segments, if there is a Transfer or an Involuntary Withdrawal during the taxable year, the Profit and Loss shall be allocated between the original Interest Holder and the successor on the basis of the number of days each was an Interest Holder during the taxable year; provided, however, the Company’s taxable year shall be segregated into two or more segments in order to account for Profit, Loss or proceeds attributable to a Capital Transaction or to any other extraordinary non-recurring items of the Company.

 

4.5.4. The Management Committee is hereby authorized, upon the advice of the Company’s tax counsel, to amend this Article IV to comply with the Code and the Regulations promulgated under Code Section 704(b); provided, however, that no amendment shall materially affect distributions to an Interest Holder without the Interest Holder’s prior written consent.

 

 11 

 

 

Section V

Management and Management Committee: Rights, Powers, Duties and Obligations

 

5.1. Management and Management Committee .

 

5.1.1. The business and affairs of the Company shall be managed under the direction and control of a management committee (the “Management Committee”), which shall consist of three (3) individuals, who are called Managers (each a “Manager,” and collectively, the “Managers”). Managers need not be Members. The Management Committee initially shall consist of two (2) individuals nominated by Trxade Health, namely Suren Ajjarapu and Prashant Patel and (1) individual nominated by Exchange Health, namely Hemanshu Pandya. If Trxade Health or Exchange Health holds less than a twenty-five percent (25%) Percentage under Exhibit A, as amended, such Member shall forfeit the right to exclusively nominate a Manager to the Management Committee as described in the preceding sentence, and in such event, the right to appoint and/or remove said Manager to the Management Committee shall be vested those Member(s) holding greater than 50% of the Interests by majority vote thereof. Except as otherwise agreed by the Members, the members of the Management Committee shall serve without compensation from the Company.

 

5.1.2. All powers of the Company shall be exercised by or under the authority of the Management Committee. Decisions of the Management Committee within its scope of authority shall be binding upon the Company and each Member.

 

5.1.3. Meetings of the Management Committee shall be held at the principal place of business of the Company or at any other place that the Management Committee may determine. In the alternative, meetings may be held by conference telephone, provided that each member of the Management Committee can hear the others. The presence of at least two (2) of the Members of the Management Committee shall constitute a quorum for the transaction of business. Meetings shall be held once each month, or otherwise in accordance with a schedule established by the Management Committee. In addition, any member of the Management Committee may convene a meeting thereof by phone, upon at least four (4) business days’ prior written notice to the other members. The Management Committee also may make decisions, without holding a meeting, by written consent of a majority of the members of the Management Committee. Minutes of each meeting and a record of each decision shall be kept by the designee of the Management Committee and shall be given to the Members promptly after the meeting.

 

5.1.4. Decisions of the Management Committee shall require the approval of at least two (2) Managers.

 

5.1.5. The Member’s having the authority to nominate a Manager may, with or without cause, at any time and from time to time and for any reason, may remove their specifically nominated Manager then acting and elect a new Manager. Any vacancy occurring for any reason in the number of Managers may be filled by the affirmative vote or written consent of the Members authorized to appoint such Manager. Additionally, if any one or more of the following events occurs, a majority of the Members may remove a Manager:

 

 12 

 

 

5.1.5.1. The Manager’s willful or intentional violation or reckless disregard of the Manager’s duties to the Company; or

 

5.1.5.2. The Members having the authority to nominate the Manager have an Involuntary Withdrawal.

 

5.1.6. The Management Committee shall, as soon as practicable, appoint an individual to supervise the day-to-day operations of the Company and such person shall be designated as President. The President shall be subject to the general supervision and control of the Management Committee and shall carry out the policy decisions made by the members of the Management Committee. At each regular meeting of the Management Committee (and, when requested by any member thereof, at any special meeting of the Management Committee), the President shall be present and shall report to the Management Committee on the operations of the Company or any other matters as any member of the Management Committee may request.

 

5.1.7. At the direction of the Management Committee, the President shall have the full power to execute, for and on behalf of the Company, any and all documents and instruments which may be necessary to carry on the business of the Company, including, without limitation, any and all deeds, contracts, leases, mortgages, deeds of trust, promissory notes, guarantees, security agreements, and financing statements pertaining to the Company’s assets or obligations. No person dealing with the President need inquire into the validity or propriety of any document or instrument executed in the name of the Company by the President, or as to the authority of the President in executing the same.

 

5.1.8. Restrictions on the Management Committee. Notwithstanding anything in this Operating Agreement to the contrary, the Management Committee shall not have any authority to take any of the following acts on behalf of the Company without the unanimous approval of all Managers on the Management Committee:

 

(a) any Capital Transaction;

 

(b) the entering into of any contract or transaction with any Member, any individual on the Management Committee, or Affiliate of any Member or and individual on the Management Committee;

 

(c) to lend, assume, or guaranty debt in excess of $500,000 in any one fiscal year;

 

(d) the engaging of the Company in any business not contemplated by Section 2.3 of this Agreement or the changing of the name of the Company or its principal office;

 

(e) the sale, conveyance, exchange, lease, mortgage, or other transfer of substanially all the assets of the Company prior to February 15, 2025;

 

(f) the Distributions of Capital Proceeds;

 

 13 

 

 

(g) the purchase, sale, lease, mortgage, encumbrance or other disposition of real property, or of any right therein, or the construction or destruction of buildings or other facilities which are not included in an approved budget;

 

(h) the entering into of any rental and lease agreements exceeding four (4) years in duration; and

 

(i) the institution of a proceeding for the Company to be adjudicated as bankrupt or insolvent, the consent to the institution of bankruptcy or insolvency proceedings against the Company, the filing of a petition, answer or consent seeking reorganization or relief under any applicable federal or state bankruptcy laws with respect to the Company, the consent to the filing of any such petition or to the appointment of a receiver, liquidator, assignee, trustee, or other similar official for the Company, or for any substantial part of its property, any assignment for the benefit of the Company’s creditors, any admission of the Company’s inability to pay its debts generally as they become due, or any action or furtherance of any such proceeding or similar action.

 

5.1.9. Limitation on Authority of Members and Manager.

 

5.1.9.1. No Member or Manager is an agent of the Company solely by virtue of being a Member or Manager, and no Member or Manager has authority to act for the Company solely by virtue of being a Member or Manager. Managers may only act as an agent of the Company or act for the Company with express authority from the Management Committee.

 

5.1.9.2. This Section 5.1 supersedes any authority granted to the Members or Manager pursuant to the Act. Any Member or Manager who takes any action or binds the Company in violation of this Section 5.1 shall be solely responsible for any loss and expense incurred by the Company as a result of the unauthorized action and shall indemnify and hold the Company harmless with respect to the loss or expense.

 

5.2. Meetings of and Voting by Members.

 

5.2.1. A meeting of the Members may be called at any time by any Manager or by those Members holding at least a majority of the Percentages then held by Members. Meetings of Members shall be held at the Company’s principal place of business or at any other place designated by the Person calling the meeting. Not less than ten (10) nor more than ninety (90) days before each meeting, the Person calling the meeting shall give written notice of the meeting to each Member entitled to vote at the meeting. The notice shall state the time, place, and purpose of the meeting. Notwithstanding the foregoing provisions, each Member who is entitled to notice waives notice if before or after the meeting, the Member signs a waiver of the notice which is filed with the records of Members’ meetings, or if such Member is present at the meeting in person or by proxy. Unless this Agreement provides otherwise, at a meeting of Members, the presence in person or by proxy of Members holding not less than a majority of the Percentages then held by Members constitutes a quorum. A Member may vote either in person or by written proxy signed by the Member or by his duly authorized attorney in fact.

 

 14 

 

 

5.2.2. Except as otherwise provided in this Agreement, wherever this Agreement requires the approval of the Members, the affirmative vote of members holding a majority or more of the Percentages then held by Members shall be required to approve the matter.

 

5.2.3. In lieu of holding a meeting, the Members may vote or otherwise take action by a written instrument indicating the consent of Members holding a majority of the Percentages then held by Members.

 

5.3. Personal Services.

 

5.3.1. No Member shall be required to perform services for the Company solely by virtue of being a Member. Unless approved by the Management Committee, no Member shall perform services for the Company or be entitled to compensation for services performed for the Company.

 

5.3.2. Unless approved by a Supermajority Interest, the Managers on the Management Committee shall not be entitled to compensation for services performed for the Company. However, upon substantiation of the amount and purpose thereof, the Management Committee shall be entitled to reimbursement for expenses reasonably incurred in connection with the activities of the Company.

 

5.4. Duties of Parties, Non-Competition.

 

5.4.1. The Managers on the Management Committee shall devote such time to the business and affairs of the Company as is necessary to carry out the Management Committee’s duties set forth in this Agreement.

 

5.4.2. Except as otherwise expressly provided in this Section 5.4.3, nothing in this Agreement shall be deemed to restrict in any way the rights of the Management Committee, Manager or any Member, or of any Affiliate of the Managers on the Management Committee or any Member, to conduct any other business or activity whatsoever, and the Management Committee, Managers or any Member shall not be accountable to the Company or to any Member with respect to that business or activity. The organization of the Company shall be without prejudice to their respective rights (or the rights of their respective Affiliates) to maintain, expand, or diversify such other interests and activities and to receive and enjoy profits or compensation therefrom. Each Member waives any rights the Member might otherwise have to share or participate in such other interests or activities of the Management Committee or any other Member or the Management Committee’s or Member’s Affiliates. Notwithstanding the foregoing, however, without the prior written approval of the unanimous consent of the Management Committee, a Manager or Member may not, directly or indirectly, (a) enter into a business relationship with any other Person that is materially adverse to the Business of the Company or an Affiliate of the Company, or (b) cause any Person to reduce or terminate its relationship with the Company or any Affiliate of the Company. The foregoing covenants shall apply to each Member, and each Manager during the period in which each Manager is a Member.

 

 15 

 

 

5.4.3. Each Member understands and acknowledges that the conduct of the Company’s business may involve business dealings and undertakings with Members and their Affiliates. In any of those cases, those dealings and undertakings shall be at arm’s length and on commercially reasonable terms as determined by the Management Committee.

 

5.5. Liability and Indemnification.

 

5.5.1. The individuals on the Management Committee shall not be liable, responsible, or accountable, in damages or otherwise, to any Member or to the Company for any act performed by the Management Committee within the scope of the authority conferred on the Management Committee by this Agreement, except for fraud, gross negligence, willful misconduct, or an intentional breach of this Agreement.

 

5.5.2. The Company shall indemnify individuals on the Management Committee for any act performed by such individual on the Management Committee within the scope of the authority conferred on the Management Committee by this Agreement, except for fraud, gross negligence, willful misconduct or an intentional breach of this Agreement.

 

5.6. Power of Attorney.

 

5.6.1. Grant of Power. Each Member constitutes and appoints the Management Committee as the Member’s true and lawful attorney-in-fact (“Attorney-in-Fact”), and in the Member’s name, place and stead, to make, execute, sign, acknowledge, and file:

 

5.6.1.1. the Certificate of Formation;

 

5.6.1.2. all documents (including amendments to the Certificate of Formation) which the Attorney-in-Fact deems appropriate to reflect any amendment, change, or modification of this Agreement;

 

5.6.1.3. any and all other certificates or other instruments required to be filed by the Company under the laws of the State of Delaware or of any other state or jurisdiction, including, without limitation, any certificate or other instruments necessary in order for the Company to continue to qualify as a limited liability company under the laws of the State of Delaware;

 

5.6.1.4. one or more fictitious or trade name certificates; and

 

5.6.1.5. all documents which may be required to dissolve and terminate the Company and to cancel its Certificate of Formation.

 

5.6.2. Irrevocability. The foregoing power of attorney is irrevocable and is coupled with an interest, and, to the extent permitted by applicable law, shall survive the death or disability of a Member and be binding on such Member’s heirs. It also shall survive the Transfer of an Interest, except that if the transferee is approved for admission as a Member, this power of attorney shall survive the delivery of the assignment for the sole purpose of enabling the Attorney-in-Fact to execute, acknowledge and file any documents needed to effectuate the substitution. Each Member shall be bound by any representations made by the Attorney-in-Fact acting in good faith pursuant to this power of attorney, and each Member hereby waives any and all defenses which may be available to contest, negate or disaffirm the action of the Attorney-in-Fact taken in good faith under this power of attorney.

 

 16 

 

 

5.7. Access to Information

 

5.7.1. Upon request, each Member shall be sent quarterly and annually, but in no event later than 90 days after the close of the company’s fiscal quarter or year, as applicable, a copy of the company’s federal, state, and local tax returns and such other information as the company shall prepare with respect to its business and financial condition. Upon reasonable demand and for any purpose reasonably related to the Member’s Interest as a Member, each member, at the principal offices of the company, may inspect and copy (1) a current list of the names and last known addresses of each member and manager; (2) a listing showing the value and form of capital contribution made by each member; (3) a copy of the Certificate of Formation, the limited liability company agreement of the company, and any amendments thereto; and (4) all other information regarding the affairs of the company.

 

5.7.2. The Management Committee shall have the absolute discretion to withhold any information from a member requested under Section 5.7.1(4) above that the manager deems to be in the nature of trade secrets or confidential information, the disclosure of which would not be in the best interest of the Company. The Management Committee shall not disclose any information to members which is required by law or agreement with a third-party to be kept confidential.

 

5.8       Transactions Between the Company and the Members. .Notwithstanding that it may constitute a conflict of interest, the Members and their Affiliates may engage in any transaction with the Company so long as such transaction is not expressly prohibited by this Agreement and so long as the terms and conditions of such transaction, on an overall basis, are fair and reasonable to the Company and are at least as favorable to the Company as those that are generally available from persons capable of similarly performing them, and the Management Committee unanimously approves the transaction in writing.

 

Section VI

Transfer of Interests, Sales of Interests, and Withdrawals of Members

 

6.1. Transfers.

 

6.1.1. No Person may Transfer all or any portion of or any interest or rights in the Person’s Membership Rights or Interest unless the following conditions (“Conditions of Transfer”) are satisfied:

 

6.1.1.1. The Transfer will not require registration of Interests or Membership Rights under any federal or state securities laws;

 

 17 

 

 

6.1.1.2. The transferee delivers to the Company a written instrument agreeing to be bound by the terms of this Agreement.

 

 

6.1.1.3. The Transfer will not result in the Company being subject to the Investment Company Act of 1940, as amended;

 

6.1.1.4. The transferor or the transferee delivers the following information to the Company: (i) the transferee’s taxpayer identification number and (ii) the transferee’s initial tax basis in the Transferred Interest;

 

6.1.1.5. The transfer will not result in the Company being taxed as a corporation for purposes of federal or state income tax purposes;

 

6.1.1.6 . The transfer conforms with the other provision under this Section 6.

 

6.1.2. If the Conditions of Transfer are satisfied, as well as another other conditions and restrictions founder herein, including but not limited to those restrictions under Sections this Section 6, then a Member or Interest Holder may Transfer all or any portion of that Person’s Interest. The Transfer of an Interest pursuant to this Section 6.1 shall not result, however, in the Transfer of any of the transferor’s other Membership Rights, if any, and the transferee of the Interest shall have no right to: (i) become a Member without the consent of the Members required by this Agreement; or (ii) exercise any Membership Rights other than those specifically pertaining to the ownership of an Interest or otherwise referenced herein.

 

6.1.3. Each Member hereby acknowledges the reasonableness of the prohibition contained in this Section 6.1 in view of the purposes of the Company and the relationship of the Members. The Transfer of any Membership Rights or Interests in violation of the prohibition contained in this Section 6.1 shall be deemed invalid, null and void, and of no force or effect. Any Person to whom Membership Rights are attempted to be transferred in violation of this Section shall not be entitled to vote on matters coming before the Members, participate in the management of the Company, act as an agent of the Company or have any other rights in or with respect to the Membership Rights.

 

 18 

 

 

6.1.4. Right of First Refusal

 

6.1.4.1. If any Member (or legal representative) desires to sell (collectively for purposes of this Section 6.1.4, the “Selling Member”) all or any part of such Selling Member’s Interest or Membership Rights, as applicable (collectively for purposes of this Section 6.1.4, the “Offered Membership Interest”), and such Selling Member receives an acceptable bona fide third party offer for the purchase of the Offered Membership Interest, the Selling Member shall comply with the following provisions:

 

6.1.4.2. The Selling Member shall deliver written notice to the Management Committee and to the other Members (the “Non-Selling Members”) stating (i) the Selling Member’s bona fide intention to sell the Offered Membership Interest, (ii) the size or amount of the Offered Membership Interest, (iii) the purchase price, terms of payment and other material terms and conditions contained in the offer received by the Member, and (iv) the name and address of the proposed purchaser (such notice, the “Sale Notice”). Within thirty (30) days after receipt of the Sale Notice (the “Company Option Period”), the Management Committee shall have the right, but not the obligation, to elect on behalf of the Company to purchase all, but not less than all, of the Offered Membership Interest at the price and the other terms and conditions set forth in the Sale Notice and the terms of payment provided therein. If the Sale Notice provides for the payment of non-cash consideration, the Company may elect to pay the consideration in cash equal to the good faith estimate of the present fair market value of the non-cash consideration offered as determined by the Management Committee. If the Management Committee exercises such right on behalf of the Company within the Company Option Period, the Management Committee shall give written notice of that fact to the Selling Member and the Non-Selling Members.

 

6.1.4.3. If the Management Committee fails to elect on behalf of the Company to purchase the entire Offered Membership Interest within the Company Option Period, then, within thirty (30) days after the expiration of the Company Option Period, the Non-Selling Members shall have the right, but not the obligation, to elect to purchase all, but not less than all, of the Offered Membership Interest at the price and terms of payment designated in the Sale Notice or the terms of payment provided therein. If the Sale Notice provides for the payment of non-cash consideration, the Non-Selling Members each may elect to pay the consideration in cash equal to the good faith estimate of the present fair market value of the non-cash consideration offered as determined by the Management Committee.

 

6.1.4.4. Each Non-Selling Member desiring to purchase the Offered Membership Interest shall notify the Management Committee in writing of the Non-Selling Member’s desire to purchase such Offered Membership Interest. The failure of any Non-Selling Member to submit a notice within the applicable period shall constitute an election on the part of that Non-Selling Member not to purchase any of the Offered Membership Interest that may be sold. The Non-Selling Members shall each be entitled to purchase a portion of the Offered Membership Interest in the same proportion that the Interest of such Non-Selling Member bears to the aggregate of the Interests of all of the Non-Selling Members. If any Non-Selling Members elect to purchase none or less than all of such Non-Selling Member’s pro rata share of the Offered Membership Interest (such remaining unpurchased Offered Membership Interests, the “Remaining Interests”), then each of the other Non-Selling Members can elect to purchase that percentage of the Remaining Interests (such electing Non-Selling Members, the “Overallotment Members”) equal to the quotient obtained by dividing (i) the Overallotment Member’s Interest, by (ii) the aggregate Interest owned by all Overallotment Members.

 

6.1.4.5. If both the Company and the Non-Selling Members elect not to purchase, or default in their obligation to purchase, all of the Offered Membership Interest, then the Selling Member may sell the Offered Membership Interest to the purchaser described in the Sale Notice, provided such sale (i) is completed within thirty (30) days after the earlier of (a) the expiration of the Company’s and the Non-Selling Members’ right to purchase the Offered Membership Interest, and (b) the default in the obligation of the Company or the Non-Selling Member to purchase, and (ii) is made on terms no less favorable to the Selling Member than as designated in the Sale Notice. Such purchaser may only be admitted as a Member of the Company pursuant to the requirements set forth in Section 6.1.8.

 

 19 

 

 

6.1.4.6. Compliance with this Section 6.1.4 does not modify any of the transfer restrictions in this Section 6 or otherwise entitle a Member to transfer the Member’s Interest or Membership Rights other than in the manner prescribed by this Section 6, including but not limited to the restrictions found under Section 6.1.2. If the Offered Membership Interest is not sold within the time periods provided herein, the Selling Member must give notice in accordance with this 6.1.4 prior to any other or subsequent transfer of the Offered Membership Interest.

 

6.1.5. Tag-Along Right. In addition to the Right of First Refusal under Section 6.1.4 above and other restrictions found herein, no Selling Member shall voluntarily transfer their Offered Membership Interest to a third party (“Third Party”) unless the other non-transferring Members (“Other Members”) are given the opportunity (“Tag-Along Right”) to transfer to the Third Party a portion of their Interests at a price and on terms and subject to conditions that are no less favorable to the Other Members than those to the Selling Member. All electing Other Members and the Selling Member shall be entitled to sell the same percentage of their Interests. The Other Members may exercise the Tag-Along Right by giving written notice of such exercise to the Selling Member during the Option Periods specified under Section 6.1.4 above and the Selling Member has provided written notice to the Other Members of such proposed transfer containing a copy of the offer of the Third Party in the Sale Notice specified under Section 6.1.4 above. If some or all of the Other Members exercise the Tag-Along Right, then the Selling Member shall not transfer any of the Selling Member Interests to the Third Party unless the Third Party also acquires the Interests of the Other Member(s) in accordance with the provisions of this Section 6.1.5. Compliance with this Section 6.1.5 does not modify any of the transfer restrictions in this Section 6 or otherwise entitle a Member to transfer the Member’s Interest or Membership Rights other than in the manner prescribed by this Section 6, including but not limited to the restrictions found under Section 6.1.2.

 

6.1.6. Drag-Along Rights.

 

6.1.6.1. If at any time a Member or a group of Members owning in excess of 50% of the total Interests (whether one or more, the “Selling Holder”) proposes to transfer (“Proposed Transfer”) all of the Interests to a Third Party in an arm’s-length transaction, and such Proposed Transfer is approved by the Management Committee, the Selling Holder shall have the right (“Drag-Along Right”) to require all (but not less than all) of the other Interest Holders (“Other Interest Holders”) to sell in the Proposed Transfer all (but not less than all) of the Interests then owned by the Other Interest Holders on the same terms and conditions as are obtained by the Selling Holder (consistent with the economic interests of such Other Interest Holders under the terms of this Agreement). Each Other Interest Holder hereby agrees to take all reasonable steps necessary to enable such Other Interest Holder to comply with the provisions of this Section 6.1.6, including executing and performing a purchase and sale, merger or other applicable acquisition agreement on the same terms as the Selling Holder. The Selling Holder shall keep each Other Interest Holder advised in writing of, and consult on a timely basis with each Other Interest Holder concerning, any transfer with respect to which the Selling Holder has exercised the Drag-Along Right.

 

 20 

 

 

6.1.6.2. To exercise the Drag-Along Right, the Selling Holder shall give each Other Interest Holder and the Company a written notice (“Drag-Along Notice”) containing (i) confirmation that the Third Party proposes to acquire all of the Interests, (ii) the name and address of the Third Party, and (iii) the proposed purchase price, terms of payment and other material terms and conditions of the Third Party’s offer. Each Other Interest Holder shall thereafter be obligated to sell all (but not less than all) of its Interests (and all rights associated therewith) as provided in such Drag-Along Notice, provided that the transaction is consummated within 120 days after the delivery of the Drag-Along Notice. If the sale is not consummated within such 120-day period, then each Other Interest Holder shall no longer be obligated to sell such Interest Holder’s Interests or Interests pursuant to that specific Drag-Along Notice, but shall remain subject to the provisions of this Section 6.1.6. with respect to any subsequent transfer to which the Drag-Along Right would apply.

 

6.1.7. Preemptive Rights.

 

6.1.7.1 No Interests of any class, or any rights, warrants, options or privileges to acquire Interest of any class, shall be issued by the Company without consent of the Management Committee; and, in the event of any issuance of any Interests, Membership Rights or rights, warrants, options or privileges to acquire Interests (collectively, “Equity Interests”), each Member shall have the right and option to acquire (on the same terms and conditions upon which the Equity Interests are proposed to be issued) a pro rata portion of the Equity Interests that are proposed to be issued (based upon the Member’s then-current percentage ownership of Interests), immediately before those Equity Interests are offered for sale or issuance, it being the parties’ intent, among other things, that each Member shall have the right, option and privilege to acquire a sufficient number of Equity Interests on those terms and conditions to avoid the dilution of his or her percentage ownership of and rights (including, without limitation, voting rights) in the Company. The Company shall deliver written notice (the “Preemptive Notice”) to each Member prior to the date of any proposed issuance of and such offered Equity Interests. Each Member shall have a period of twenty one (21) days after the date the Preemptive Notice is given (within which to elect to purchase the Member’s eligible amount at the price and upon the terms specified above by giving written notice to the Company. The Members at all times shall vote their Interests to assure that the mutual promises contained in this Section 6.1.7 are carried out.

 

6.1.7.2 Notwithstanding the foregoing, the preemptive rights established by this Section 6.1.7 shall have no application to any of the following securities:

 

(a) Equity Interests to be issued after the Effective Date to employees, officers or directors of, or consultants or advisors to the Company or any subsidiary of the Company, pursuant to stock purchase or stock option plans or other arrangements that are approved by the Management Committee of the Company;

 

(b) Equity Interest issued for consideration other than cash pursuant to a merger, consolidation, acquisition or similar business combination approved by the Management Committee;

 

(c) Equity Interests issued in connection with any stock split, stock dividend or recapitalization by the Company, or in connection with any other anti-dilution rights;

 

 21 

 

 

(d) any Equity Interests issued pursuant to any equipment loan or leasing arrangement, real property leasing arrangement, or debt financing from a bank or similar financial or lending institution approved by the Management Committee;

 

(e) any Equity Interests that are issued by the Company pursuant to a registration statement filed under the Securities Act;

 

(f) Equity Interests issued in connection with any Drag Alone Right; and

 

(g) any Equity Interests issued in connection with strategic transactions involving the Company and other entities, including (i) joint ventures, manufacturing, marketing or distribution arrangements or (ii) technology transfer or development arrangements; provided that the issuance of shares therein has been approved by the Management Committee;

 

6.1.7.3. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Interests to any Member which would cause the Company to be in violation of applicable state or federal securities laws by virtue of such offer or sale or who is not an Accredited Investor at the time of such sale.

 

6.1.8 Admission of Transferee as Member. Notwithstanding anything contained herein to the contrary, the transferee of all or any portion of, or any interest or rights in, any Membership Rights shall not be entitled to become a Member or exercise any rights of a Member, as further described under Section 6.1.2. The transferee shall be entitled to receive, to the extent transferred, only the distributions and other Interest rights to which the transferor would be entitled; and the transferee shall not be admitted as a Member unless the Members unanimously consent to such admission.

 

6.2. Voluntary Withdrawal. Any Member shall have the right or power to effect a Voluntary Withdrawal from the Company, provided that such member must give ninety (90) days prior written notice to all Members. Any Member who effectuates a Voluntary Withdrawal shall not be permitted to receive the fair value or any value of the Member’s Interest or Membership Rights as of the date of the Voluntary Withdrawal as otherwise provided in Section 18-604 of the Act, and may instead effect a Voluntary Withdrawal by forfeiture of its Interests (and all Membership Rights and other rights associated therewith) without compensation or consideration back to the Company; provided however, that if Trxade Health (a) effectuates a Voluntary Withdrawal prior to February 15th, 2024 (the “Earn Out Period”), and (b) the Company has failed to meet any of the Revenue Targets required by the Earn Out Payments prior the expiration of the Earnout Period, then all obligations of Trxade Health under the Earn Out Payments and the Note shall terminate, as further described therein.

 

6.3. Involuntary Withdrawal. Immediately upon the occurrence of an Involuntary Withdrawal, the successor of the member who has effectuated an Involuntary Withdrawal shall thereupon become an Interest Holder but shall not become a Member. If the Company is continued by vote of the members, the successor Interest Holder shall have all the rights of an Interest Holder but shall not be entitled to receive the fair market value of the Member’s Interest as of the date of the Involuntary Withdrawal from the Company as otherwise provided in Section 18-604 of the Act.

 

 22 

 

 

6.4 Trxade Buyout Provision.

 

6.4.1. Trxade Health, or its assigns (collectively, the “Purchaser”), may at any time by written notice (the “Buyout Notice”) to any other Member (the “Seller”), offer to purchase all (but not less than all) of such Seller’s Membership Interests at a purchase price as stated in the Buyout Notice (the “Buyout Price”), which shall be calculated and payable pursuant to the DCF Valuation Method specified on Exhibit F If the Buyout Price is paid to Exchange Health or its successors or assigns, any remaining amounts payable under the Note become immediately due and payable, as further described under Exhibit F.

 

6.4.1. Upon receipt of the Buyout Notice, within thirty (30) days after receipt of the Buyout Notice, the Purchaser shall purchase, and the Seller shall sell all its Interests to the Purchaser at the Buyout Price. Each Member acknowledges that by executing this Agreement, he, she or it hereby waives any subsequent objection to the enforcement of the deemed election set forth in herein.

 

6.4.2. The applicable purchase price to the Seller for Interests shall be paid no later than ten (10) days following the determination of such Buyout Price, or as otherwise agreed by the Seller and the Purchaser.

 

Section VII

Dissolution, Liquidation, and Termination of the Company

 

7.1. Events of Dissolution. The Company shall be dissolved upon the happening of any of the following events:

 

7.1.1. when the period fixed for its duration in Section 2.4 has expired;

 

7.1.2. upon the unanimous written agreement of all of the Management Committee;

 

7.1.3. upon the sale of all or substantially all of the assets of the company; or

 

7.1.4. the entry of a decree of judicial dissolution under 6 Del. C. § 18-802.

 

7.2. Procedure for Winding Up and Dissolution. If the Company is dissolved, the Management Committee shall wind up its affairs. If there shall be no Management Committee, the Members shall elect a Person to wind up the affairs of the Company. On winding up of the Company, the assets of the Company shall be distributed, first, to creditors of the Company, including Interest Holders who are creditors, in satisfaction of the liabilities of the Company, and then to the Interest Holders in proportion to their respective Capital Accounts.

 

7.3. Filing of Certificate of Cancellation. Upon completion of the winding up of the affairs of the Company, the Management Committee shall promptly file a Certificate of Cancellation with the Office of the Secretary of State of the State of Delaware. If the Management Committee has caused the dissolution of the Company, whether voluntarily or involuntarily, then a Person selected by a majority vote of the Members to wind up the affairs of the Company shall file the Certificate of Cancellation.

 

 23 

 

 

Section VIII

Books, Records, Accounting, and Tax Elections

 

8.1. Bank Accounts. All funds of the Company shall be deposited in a bank account or accounts maintained in the Company’s name. The Management Committee shall determine the institution or institutions at which the accounts will be opened and maintained, the types of accounts, and the Persons who will have authority with respect to the accounts and the funds therein.

 

8.2. Books and Records.

 

8.2.1. The Management Committee shall keep or cause to be kept complete and accurate books and records of the Company and supporting documentation of the transactions with respect to the conduct of the Company’s business. The records shall include, but not be limited to, complete and accurate information regarding the state of the business and financial condition of the Company, a copy of the Certificate of Formation and Limited Liability Company Agreement and all amendments to the Certificate of Formation and the Limited Liability Company Agreement; a current list of the names and last known business, residence, or mailing addresses of all Members; and the Company’s federal, state, or local tax returns.

 

8.2.2. The books and records shall be maintained in accordance with generally accepted accounting practices and shall be available at the Company’s principal office for examination by any Member or the Member’s duly authorized representative at any and all reasonable times during normal business hours for any purpose reasonably related to such Member’s interest as a Member.

 

8.2.3. Each Member shall reimburse the Company for all costs and expenses incurred by the Company in connection with the Member’s inspection and copying of the Company’s books and records.

 

8.3. Annual Accounting Period. The annual accounting period of the Company shall be its taxable year. The Company’s taxable year shall be selected by the Management Committee, subject to the requirements and limitations of the Code.

 

8.4. Reports. Within seventy-five (75) days after the end of each taxable year of the Company, the Management Committee shall cause to be sent to each Person who was a Member at any time during the accounting year then ended: (i) an annual compilation report, prepared by the Company’s independent accountants in accordance with standards issued by the American Institute of Certified Public Accountants, and (ii) a report summarizing the fees and other remuneration paid by the Company to any Member, the Management Committee or any Affiliate in respect of the taxable year. In addition, within seventy-five (75) days after the end of each taxable year of the Company, the Management Committee shall cause to be sent to each Person who was an Interest Holder at any time during the taxable year then ended, that tax information concerning the Company which is necessary for preparing the Interest Holder’s income tax returns for that year. At the request of any Member, and at the Member’s expense, the Management Committee shall cause an audit of the Company’s books and records to be prepared by independent accountants for the period requested by the Member.

 

 24 

 

 

8.5. Tax Matters Partner. The Management Committee shall be the Company’s Partnership Representative (“Partnership Representative”). The Partnership Representative shall have all powers and responsibilities provided in Code Sections 6221 et seq. The Partnership Representative shall keep all Members informed of all notices from government taxing authorities which may come to the attention of the Partnership Representative. The Company shall pay and be responsible for all reasonable third-party costs and expenses incurred by the Partnership Representative in performing those duties. A Member shall be responsible for any costs incurred by the Member with respect to any tax audit or tax-related administrative or judicial proceeding against any Member, even though it relates to the Company. The Partnership Representative may not compromise any dispute with the Internal Revenue Service without the approval of the Members. The Partnership Representative, if the Company is so eligible, will elect out of the unified partnership audit rules pursuant to Code Section 6221(b). If the Partnership Representative determines that the Company is not eligible to make that election under Code Section 6221(b), the Partnership Representative shall make the election under Code Section 6226 to push the tax liability out to the Members.

 

8.6. Tax Elections. The Management Committee shall have the authority to make all Company elections permitted under the Code, including, without limitation, elections of methods of depreciation and elections under Code Section 754. The decision to make or not make an election shall be at the Management Committee’s sole and absolute discretion, subject to the Management Committee’s obligations to act in the best interest of the Company and its Members.

 

8.7. Title to Company Assets.

 

8.7.1. Except as provided in Section 8.7.2, all real and personal property acquired by the Company shall be acquired and held by the Company in its name.

 

8.7.2. The Management Committee may direct that legal title to all or any portion of the Company’s Assets be acquired or held in a name other than the Company’s name. Without limiting the foregoing, the Management Committee may cause title to be acquired and held in its name or in the names of trustees, nominees, or straw parties for the Company. It is expressly understood and agreed that the manner of holding title to the Company’s Assets (or any part thereof) is solely for the convenience of the Company, and all of Assets shall be treated as Company Assets.

 

 25 

 

 

Section IX

General Provisions

 

9.1. Assurances. Each Member shall execute all such certificates and other documents and shall do all such filing, recording, publishing, and other acts as the Management Committee deems appropriate to comply with the requirements of law for the formation and operation of the Company and to comply with any laws, rules and regulations relating to the acquisition, operation or holding of the property of the Company.

 

9.2. Notifications. Any and all notices, requests, demands, or other communications provided for hereunder, shall be given in writing by personal service, by registered or certified mail, postage prepaid, overnight delivery service, delivery charges prepaid, or by email, facsimile or other electronic means addressed to the intended recipients at the addresses set forth below or at such other addresses as the intended recipients may have designated in written notices to the other parties hereto. A notice shall be deemed to have been received when personally served or delivered or five (5) days after being mailed, or one (1) day after being sent by overnight delivery service or by email, facsimile or other electronic means Any notice to be given hereunder by the Company shall be given by the Management Committee. A notice must be addressed to an Interest Holder at the Interest Holder’s last known address on the records of the Company. A notice to the Company must be addressed to the Company’s principal office. Any party may designate, by notice to all of the others, substitute addresses or addressees for notices; and, thereafter, notices are to be directed to those substitute addresses or addressees.

 

If to Company:
SOSRx, LLC

2420 Brunello Trace
Lutz, FL 33558
Email: Suren@trxade.com

 

With copies to (which shall not constitute notice):
Steven D. Lee, Esq.
Foundation Law Group LLP
445 South Figueroa Street, Suite 3100
Los Angeles, CA 90071
Email: steve@foundationlaw.com

 

If to a Member, or the Company, at the address set forth on Exhibit A attached hereto.

 

9.3 Complete Agreement. This Agreement, together with the Exhibits referenced herein, constitutes the complete and exclusive statement of the agreement among the Members. It supersedes all prior written and oral statements, including any prior representation, statement, condition, or warranty. Except as expressly provided otherwise herein, this Agreement may not be amended without the written consent of Supermajority Interest .

 

9.4. Applicable Law. All questions concerning the construction, validity and interpretation of this Agreement and the performance of the obligations imposed by this Agreement shall be governed by the internal law, not the law of conflicts, of the State of Delaware.

 

 26 

 

 

9.5. Section Titles. The headings herein are inserted as a matter of convenience only, and do not define, limit, or describe the scope of this Agreement or the intent of the provisions hereof.

 

9.6. Binding Provisions. This Agreement is binding upon, and inures to the benefit of, the parties hereto and their respective heirs, executors, administrators, personal and legal representatives, successors, and permitted assigns.

 

9.7. Mediation. Any controversy or claim arising out of or relating to this Agreement or any related agreement will be settled in the following manner: (a) a senior executive representing each of the Members will meet to discuss and attempt to resolve any such controversy or claim within fifteen (15) days after one Member provides written notice to the other Member requesting resolution of a controversy or claim hereunder (a “Mediation Notice”); (b) if such controversy or claim is not resolved as contemplated by clause (a) within ten (10) days after receipt of the Mediation Notice, the Members will, by mutual consent, select an independent third party in Tampa, Florida, to mediate such controversy or claim, provided that such mediation will not be binding upon any of the parties; and (c) if such controversy or claim is not resolved as contemplated by clauses (a) or (b) within thirty (30) days after initiation or request of such mediation, the parties shall proceed to arbitration under Section 9.9 below.

 

9.8 Arbitration. Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction or other equitable relief to preserve the status quo or prevent irreparable harm, the Members agree to resolve any controversy, claim, or dispute arising out of or relating to this Agreement (a “Dispute”) by binding arbitration in accordance with the Commercial Arbitration Rules of the American Arbitration Association (“AAA Rules”) whether such Dispute arose or the facts on which such Dispute is based occurred prior to or after the Effective Date. The Members agree that (i) one arbitrator shall be appointed to conduct the arbitration by mutual agreement of the parties thereto or, if the parties are unable to reach mutual agreement within thirty (30) days, then the arbitrator shall be selected pursuant to AAA procedure, (ii) all meetings of the parties to the arbitration and all hearings with respect to any such arbitration shall take place in Tampa, Florida, (iii) each party to the arbitration shall bear its own costs and expenses (including, without limitation, all attorneys’ fees and expenses, except to the extent otherwise required by applicable law), and (iv) all costs and expenses of the arbitration proceeding (such as filing fees, the arbitrator’s fees, hearing expenses, etc.) shall be borne equally by the parties to the arbitration. The Members agree that the judgment, award or other determination of any arbitration under the AAA Rules shall be final, conclusive and binding on all of the parties to the arbitration. Nothing in this section shall prohibit any Member from instituting litigation to enforce any final judgment, award or determination of the arbitration. Each Member hereby irrevocably submits to the jurisdiction of the Delaware Court of Chancery, and agrees that either court shall be the exclusive forum for the enforcement of any such final judgment, award or determination of the arbitration. Each Member irrevocably consents to service of process by registered mail or personal service and waives any objection on the grounds of personal jurisdiction, venue or inconvenience of the forum.

 

9.9. Terms. Common nouns and pronouns shall be deemed to refer to the masculine, feminine, neuter, singular, and plural, as the identity of the Person may in the context require.

 

9.10. Separability of Provisions. Each and every provision of this Agreement shall be considered separable; and if, for any reason, any provision or provisions herein are determined to be invalid and contrary to any existing or future law, such invalidity shall not impair the operation of or affect those portions of this Agreement which are valid.

 

9.11. Counterparts. This Agreement may be executed simultaneously in two or more counterparts, including electronically transmitted counterparts, each of which shall be deemed an original, and all of which, when taken together, constitute one and the same document. The signature of any party to any counterpart shall be deemed a signature to, and may be appended to, any other counterpart.

 

[SIGNATURE PAGE FOLLOWS]

 

 27 

 

 

IN WITNESS WHEREOF, the parties have executed, or caused this Agreement to be executed, under seal, as of the date set forth hereinabove.

 

MEMBERS:

 

EXCHANGE HEALTH, LLC

 

     
By: Hemanshu Pandya  
Title: President  

 

TRXADE HEALTH, INC.

 

     
By: Suren Ajjarapu, CEO  

 

Exhibits

 

Exhibit A: Members and Interests and Contributions

Exhibit B: Note

Exhibit C: Earn Out Payment

Exhibit D: Distribution Agreement

Exhibit E: Asset Contribution Agreement

Exhibit F: DCF Valuation Method

 

 28 

 

 

Exhibit 10.1

 

EXHIBIT B

 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. IT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.

 

NON RECOURSE PROMISSORY NOTE

 

$500,000.00   Tampa, FL
     
    February 15, 2022

 

TRxADE HEALTH, INC. , a Delaware corporation (“Maker”) hereby promises to pay to the order of Exchange Health, LLC, a Michigan limited liability company (“Lender”), or its successors or assigns, in lawful money of the United States of America, the lesser of FIVE HUNDRED THOUSAND DOLLARS ($500,000.00) or the principal balance outstanding under this Promissory Note, together with accrued and unpaid interest thereon, at the rate or rates set forth below, and on the dates and in the amounts set forth below (the “Maturity Date”).

 

This Promissory Note is made in connection with that certain Limited Liability Company Agreement, dated as of the date hereof (“Company Agreement”), by and among SOSRx, LLC, a limited liability company (“Company”), Maker and Lender, together with the ancillary documents referenced therein.

 

The Lender’s Interests and associated Membership Rights (as defined in the Company Agreement) are collectively referred to herein as its “Pledged Collateral,” and the Pledged Collateral is the sole and exclusive security for Maker’s performance of this obligation under this Promissory Note. Therefore, this Promissory Note is a non-recourse obligation, secured solely by the Pledged Collateral. Notwithstanding anything to the contrary stated herein, Lender agrees that for payment of all amounts due under this Promissory Note it will look solely to the Pledged Collateral, and no other assets of Maker or the Company shall be subject to levy, execution or other enforcement procedure for the satisfaction of the remedies of Lender, or for any payment required to be made under this Promissory Note.

 

The unpaid principal amount and accrued interest of this Promissory Note shall bear interest at a rate per annum equal to PRIME plus Two Percent (2%) calculated on the basis of a 365-day year and the actual number of days elapsed.

 

The principal amount of this Promissory Note shall be payable in installments. The first payment of $166,666.67 shall be due and payable, together with any unpaid accrued interest thereupon, on February 15, 2023; The remaining payments shall be due in eight (8) equal installments of $41, 666.67, together with any unpaid accrued interest thereupon, at the end of every full fiscal quarter, beginning, June 20, 2023.

 

 
 

 

Notwithstanding the foregoing, pursuant to the terms and conditions of the Company Agreement and its related Exhibits, if (a) Maker effectuates a Voluntary Withdrawal under Section 6.2 of the Company Agreement prior to February 15, 2024 (the “Earn Out Period”), and (b) the Company has failed to meet any of the Revenue Targets required by the Earn Out Payments prior the expiration of the Earnout Period, then all remaining amounts of interest and principal not yet due and payable under this Promissory Note shall immediately terminate and all related indebtedness evidenced hereby shall be deemed canceled.

 

This Promissory Note may be prepaid by Maker, at its discretion, in whole or in part at any time, without premium or penalty.

 

In the event that Maker is delinquent to pay when due (whether at maturity, by reason of acceleration or otherwise) any principal of or interest on this Promissory Note, then if such payment of principal or interest is not made within fifteen (15) days of the due date, then Lender may declare an additional interest fee of 2% of the delinquent amount. If the delinquency is thirty (30) days or more from the due date, then Lender may declare another additional interest fee of 3%, to make a total of 5%, for the delinquent payment.

 

In the event that Maker shall fail to pay when due (whether at maturity, by reason of acceleration or otherwise) any principal of or interest on this Promissory Note, then if such payment of principal or interest is not made within sixty (60) days of the due date, then Lender may declare all obligations (including without limitation, outstanding principal and accrued and unpaid interest thereon) under this Promissory Note to be immediately due and payable without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived.

 

This Promissory Note is being delivered in, is intended to be performed in, shall be construed and interpreted in accordance with, and be governed by the internal laws of, the State of Delaware, without regard to principles of conflict of laws.

 

This Promissory Note may only be amended, modified or terminated by an agreement in writing signed by the party to be charged. This Promissory Note shall not be transferred without the express written consent of all parties.

 

IN WITNESS WHEREOF, Maker has caused this Promissory Note to be issued as of the date first written above.

  

  TRxADE HEALTH, INC.
   
  By:  
    Suren Ajjarapu, CEO

 

 

 

 

Exhibit 10.2

 

DISTRIBUTION SERVICES AGREEMENT

 

This Distribution Services Agreement (the “Agreement”) is made effective the 15th day of February, 2022 (the “Effective Date”), by and between SOSRx LLC, A Delaware Corporation, with offices at 2420 Brunello Trace, Lutz, FL 33558 (“SOSRx”), and Integra Pharma Solutions LLC with offices at 6308 Benjamin Rd, Unit 708, Tampa, FL (“Supplier”). References to the Agreement include the Schedules and Exhibits to this Agreement, if any.

 

BACKGROUND:

 

SOSRx operates an online e-commerce site where its “Members” purchase pharmaceutical and other medical products from “Manufacturers.”

 

SOSRx desires to have Supplier facilitate the distribution of Manufacturer’s products purchased on the SOSRx platform to its Members, and Supplier desires to accept such engagement.

 

TERMS AND CONDITIONS:

 

NOW, THEREFORE, for the reasons described in the Background above and in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1. APPOINTMENT OF MEMBERS; COMMITMENT BY SUPPLIER AND SOSRX

 

A. Appointment. Supplier hereby appoints each SOSRx Member an active account for Manufacturer Non-Control (Schedule 2-5 as classified by the US Drug Enforcement Agency) products bought on the SOSRx platform (individually and collectively referred to as “Products”). For purposes of this Agreement, the term “Members” will mean the entities recognized by SOSRx as members from time to time during the term of this Agreement. SOSRx will notify Supplier of any changes to its membership.

 

B. Sales to Members. Supplier will sell Products to SOSRx Members on the terms and conditions set forth in this Agreement as it may be amended as provided herein.

 

C. SOSRx’s commitment to Supplier. SOSRx hereby commits to use its best commercial efforts to notify its Members of the terms of this Agreement.

 

2. TERM AND TERMINATION

 

A. Term. This Agreement is effective as of the Effective Date and will continue in effect until December 31, 2023 and automatically renews each year until termination. Reference to the terms of this Agreement will include any renewal or extension of the term.

 

B. Termination. This Agreement may be terminated in whole or in part by either party as a result of a material breach of this Agreement by the other party if such breach is not cured within 30 days after notice of such breach by the non-breaching party. Except as otherwise provided in this Agreement, termination as herein provided is the sole and exclusive remedy for breach of this Agreement. For the avoidance of doubt, a breach by a Member of any purchase agreement with Supplier is not a breach by SOSRx under this Agreement or otherwise.

 

C. Effect of termination on orders. Upon the expiration or earlier termination of this Agreement, Supplier will fill all outstanding Member purchase orders in accordance with their terms and within 60 days after such expiration or termination will invoice SOSRx the logistical facilitation payment described in Paragraph 3 owed as of such date.

 

 

 

 

3. LOGISTICAL FACILITATION FEE

 

For each calendar quarter (or portion thereof) during the term of this Agreement SOSRx will remit to Supplier a logistical facilitation fee equal to 2% of the net price of each Member’s purchases during such period (the “Logistical Facilitation Fee”). Within 60 days after the end of each such period, Supplier will submit to SOSRx a quarterly recap of each Member’s purchases, accompanied by Supplier’s invoice in the amount of the logistical facilitation Fee payable by SOSRx sent to SOSRx at 2420 Brunello Trace, Lutz FL 33558.

 

4. PRODUCT PRICE; REBATES; PROMOTIONS; PAYMENT TERMS; CREDIT MATTERS

 

A. Prices. Prices for Products submitted ONLY via the SOSRx Platform, except as otherwise provided in this Paragraph 4A will be made available to Members during the term of this Agreement. Under no circumstances will Supplier charge a Member a higher price for Products than is established by this Agreement. Failure to comply with the provisions of this Paragraph 4 is a material breach of this Agreement.

 

i. Supplier may change its prices during the term of this Agreement by giving SOSRx and Member notice of such change due to unforeseen circumstances affecting direct operational costs. SOSRx and Member must approve this change prior to any shipment.

 

C. Payment terms. Unless otherwise set forth, Supplier will offer Members payment terms of net 30 days; provided however, Supplier reserves the right to require cash in advance when reasonable.

 

D. Credit matters. All monies/credit memos due to a Member (whether or not amounts are customarily paid to SOSRx as the Members’ agent) in the form of a rebate, approved product returns, shelf stock adjustment, promotional allowance, advertising allowances, or other amount due to a Member under this Agreement or otherwise (individually and collectively referred to as a “Credit Amount”) will be paid/issued to such Member within 60 days after the obligation with respect thereto is incurred. After this period, the affected Members may issue a debit memo to Supplier in the total amount of the Credit Amount owed by Supplier and deduct such amount from one or more subsequent payments to Supplier for Products.

 

i. If a Member has a credit balance, the Member reserves the right to request a check to be paid within 30 days and Supplier will comply with such request.

 

ii. Supplier will bring to the attention of the appropriate Member in writing all discrepancies affecting monies owed by either Supplier or Member to the other, including without limitation, discrepancies with respect to accounting, invoicing, debit memos, and credit memos, within 60 days from the date of the invoice.

 

iii. SOSRx makes no representation or warranty as to its Members’ ability or willingness to pay Supplier. While SOSRx may attempt to help resolve any such problem, it is the Supplier’s sole responsibility to resolve all such problems directly with Members.

 

5. SUPPLIER OBLIGATIONS

 

A. Shipment. All orders will be shipped by Supplier to Member at the location indicated on the Member’s purchase order. Unless the Member and Supplier agree otherwise, Products will be shipped FOB destination, freight prepaid. Title to and risk of loss of Products sold to Members will pass to Member upon delivery at the designated destination.

 

i. If a Member receives Products with visible damage, the Member will note the damage on the delivery slip and will promptly report the damage to Supplier’s customer service department requesting that Supplier accept prompt return of the damaged Product. Unless Supplier has established procedures Supplier will promptly provide such Member with disposition instructions. Unless otherwise instructed by Supplier, the Member will hold damaged Product for inspection for 15 days after receipt. Supplier will bear all freight and incidental costs incurred by the Member in connection with damaged Products.

 

 

 

 

ii. In the event of an incomplete shipment, a shortage in shipment, the misdirection of any delivery, or any over shipment, Supplier, upon notification by Member, will immediately contact the affected Member’s purchasing department and will comply with any reasonable directions provided with respect to the delivered and undelivered portions of the affected order(s). Supplier will be responsible for any related freight or incidental charges caused by the incorrect shipment. Members will have no obligation to accept over shipments.

 

B. Shelf life. Supplier will not ship Product to Members if the Product has expired.

 

C. Failure to supply. In the event that Supplier fails to deliver Product as scheduled, or within customary delivery time if delivery is not scheduled and such failure continues for 30 days after successfully receiving said product from the Manufacturer, Members will have the right to cancel such undelivered order(s). In the event of such failure to supply, SOSRx may cancel this Agreement with respect to such Product.

 

D. Product recall reimbursement. Supplier will comply with the guidelines for product recall reimbursement set forth in Exhibit 1 attached to this Agreement.

 

E. Statement of open receivables. Supplier will provide SOSRx with a monthly account receivable statement of all open transactions between Supplier and Members.

 

H. ADR Status. Supplier should obtain an ADR status from each manufacturer for Products supplied to a Member as a result of transactions processed by SOSRx platform.

 

I. Products Liability. Members may require a product liability certificate to be in place prior to conducting transactions with Supplier.

 

J. Licenses. Each Supplier shipping location needs to be licensed in each state that a Member is located.

 

6 RETURNS

 

A. Outdated Product. Members must follow the returns process outlined by each Manufacturer. No credit will be issued by Supplier for any outdated products.

 

B. Returns at the end of the Agreement. If this Agreement expires without being renewed or is subject to early termination, Members may not return any Products without the express permission of Supplier.

 

7. TRADE SHOW

 

Supplier agrees to participate reasonably in the SOSRx annual trade show once established.

 

8. CONTINUING GUARANTY AND INDEMNIFICATION AGREEMENT

 

A. Continuing guarantee. Supplier hereby guarantees to SOSRx and to each Member that: (i) each shipment or other delivery of any food, drugs, devices, cosmetics, or other merchandise (individually and collectively, including Products, referred to in this Paragraph 6 as “Merchandise”) now or hereafter made by Supplier, its subsidiaries, divisions or affiliated companies, to or on the order of SOSRx or any such Member will not be, at the time of such shipment or delivery, adulterated, misbranded, or otherwise prohibited within the meaning of the Federal Food, Drug and Cosmetic Act, 21 U.S.C.A. 301 et seq., as amended, and in effect at the time of said shipment or delivery (the “Act”) or within the meaning of any applicable state or local law in which the definition of adulteration or misbranding are substantially the same as those contained in the Act; (ii) such Merchandise is not, at the time of such shipment or delivery, Merchandise which may not be introduced or delivered for introduction into interstate commerce under the provisions of sections 301, 404, or 505 of the Act (21 U.S.C.A. 331, 334, and 355, respectively); and (iii) such Merchandise is Merchandise which may be legally transported or sold under the provisions of any other applicable federal, state or local law; and Supplier guarantees further that only those chemicals or sprays approved by federal, state or local authorities have been used in connection with Merchandise, and that any residue in excess of the amount allowed by any such authorities has been removed there from.

 

 

 

 

B. Supplier’s indemnity. Supplier will indemnify, defend and hold harmless SOSRx and each Member and its their parent and affiliates, its and their successors and assigns and its and their officers, directors, agents, employees and contractors (individually and collectively, the “ SOSRx Indemnities”) from and against, or will, in Supplier’s sole discretion, settle solely for money, any and all loss or liability of any nature whatsoever cognizable at law, including claims of bodily injury, death, pain and suffering or property damage and strict product liability (collectively, “Losses”) resulting from third-party claims against a SOSRx Indemnities, including any prosecution or action whatsoever by any governmental body or agency or by any private party, and will, at Supplier’s expense, including reasonable attorneys’ fees, defend each SOSRx Indemnities against claims for Losses, whether or not frivolous, that may be asserted against the SOSRx Indemnities by such third party, arising out of:

 

(i) the breach by Supplier of the provisions of this Agreement including those of Paragraph 6(A), or the condition of any Product including defect in material, workmanship, design, manufacturing or formulary, or the warnings and instructions or lack thereof for a Product; (ii) the possession, distribution, sale and/or use of, or by reason of the seizure of, any of the Products; (iii) any actual or asserted violation(s) of the Act or any other federal, state or local law or regulation by virtue of which Products sold, supplied, or delivered by the undersigned shall be alleged or determined to be adulterated, misbranded, mislabeled or otherwise not be in full compliance with, or be in contravention of, any federal, state or local law or regulation; or (vi) infringement by any of the Products of any proprietary or intellectual property rights of any person, including the infringement of any trademarks or service names, trade names, trade secrets, inventions, patents or the violation of any copyright laws or any other applicable federal, state or local laws. The provisions of this Paragraph 6B will survive the expiration or early termination of this Agreement.

 

C. Supplier’s insurance. Supplier will maintain and keep in force during the term of this Agreement and for two (2) years after full performance by Supplier under this Agreement and any orders for Products by Members hereunder, primary and noncontributing Products Liability Insurance as required by law. Upon request by SOSRx or any Member, Supplier will promptly submit to SOSRx or such Member satisfactory evidence of such insurance. All insurance coverage must be with a carrier reasonably acceptable to SOSRx. The provisions set forth in this Paragraph 6C are in addition to, and not in lieu of, any terms set forth in any purchase agreement between Supplier and a Member. In the event of any conflict between the provisions relating to insurance in such purchase agreement and this Paragraph 6C, this Agreement will prevail and be controlling; except if and to the extent that such purchase agreement provides greater insurance protection for such Member. Failure to comply with all insurance requirements set forth herein will be deemed a material breach under this Agreement.

 

9. CONFIDENTIALITY

 

This Agreement, as it may be modified, and all documents and other information provided to Supplier by SOSRx or any Member pursuant to this Agreement, or any order placed hereunder, including any information concerning prices, quantities purchased by any Member, shall be held by Supplier in strict confidence and not disclosed either directly or indirectly to any third party during the term of this Agreement and for five (5) years thereafter. Supplier acknowledges that should it breach any of its covenants in this Paragraph 7, SOSRx or the Member, as the case may be, will be irreparably harmed and will be entitled to an injunction preventing Supplier from further breaching such covenant without any further or more particularized showing of irreparable injury and without the need to post bond or other security. Such an injunction may be applied for before any Court having jurisdiction thereof. In any such proceeding, SOSRx or such Member will be entitled to recover any damages it suffers as a result of Supplier’s breach, including the recovery of any costs and reasonable attorneys’ fees incurred in enforcing its rights hereunder. Each party shall keep the terms and conditions of this Agreement and any amendments hereto confidential.

 

 

 

 

10. SOSRX’S AUTHORITY AND RELATIONSHIP WITH MEMBERS

 

SOSRx has the authority to enter into this Agreement for the benefit of its Members and to accept payments on behalf of its Members as set forth in this Agreement. Notwithstanding anything to the contrary expressed or implied in this Agreement, SOSRx has no authority to bind its Members with respect to any purchase or other commitment of any nature whatsoever. SOSRx assumes, has, and will have, no liability of any nature whatsoever; including contract and tort liability, of its Members with respect to Supplier or any other person, and nothing in this Agreement is intended to create such liability.

 

11. COMPLETE AGREEMENT

 

This Agreement set forth the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes and cancels any and all oral and written prior and all contemporaneous oral agreements between them, express or implied, with respect to such subject matter. The provisions set forth in this Agreement are in addition to, and not in lieu of, any terms set forth in any purchase agreement between Supplier and a Member. In the event of any conflict between the provisions in such purchase agreement and this Agreement, this Agreement will prevail and be controlling; except if and to the extent that such purchase agreement provides greater benefits for or provides greater protection to such Member, in which event the purchase agreement will prevail and be controlling. The parties acknowledge that no representations or promises have been made to induce either of them to enter into this Agreement other than as may be specifically set forth herein.

 

12. THIRD-PARTY BENEFICIARIES

 

The parties intend Members to be third-party beneficiaries of this Agreement in accordance with its terms and the agreements of Supplier herein are binding with respect to such Members as if such Members were direct parties to this Agreement.

 

13. MISCELLANEOUS

 

(a) This Agreement will be binding upon and inure to the benefit of the respective successors and permitted assigns of the parties hereto. (b) The rights of the parties hereunder are not assignable and any attempted assignment will be null and void. (c) Unless otherwise expressly provided in this Agreement, there are no third-party beneficiaries of this Agreement. (d) The captions set forth herein are for convenience of reference only and will not affect in any way the meaning or interpretation of this Agreement. (e) The words “including” and “include” as used in this document mean, respectively, “including, without limitation” and “include, without limitation” and shall be interpreted as not limiting the matter described by the examples given. The words “hereof,” “herein” and “hereunder” and words of similar import shall refer to all applicable provisions of this Agreement and not to any particular provision thereof unless otherwise indicated. (f) The parties will comply with all federal, state and local law applicable to their respective obligations under this Agreement. (g) The words “hereof,” “herein” and “hereunder” and words of similar import will refer to all applicable provisions of this Agreement and the agreement of which they may be a part and not to any particular provision of either. (h) Any specific right or remedy provided in this Agreement will not be exclusive or limited unless expressly excluded or limited herein, but will be cumulative with all other rights and remedies set forth in this Agreement or available under applicable law. (i) This Agreement may not be changed, altered, amended or modified except in writing signed by a duly authorized representative of the parties, specifically referring to this Agreement, and delivered by the parties each to the other. (j) The failure or refusal by a party either to insist upon the strict performance of any provision of this Agreement or to exercise any right in any one or more instances or circumstances shall not be construed as a waiver or relinquishment of such provision or right, nor shall such failure or refusal be deemed a custom or practice contrary to such provision or right. To be effective, a waiver of any provision of this Agreement must be in writing, signed by the waiving party. (k) The obligations of the parties that expressly survive the expiration or termination of this Agreement, or which by their nature are intended to survive such expiration or termination, shall so survive in accordance with their express terms or as is required to give effect to such intention, respectively. (l) This Agreement may be executed in multiple counterparts, which shall be deemed to be one and the same instrument and each of which shall be deemed enforceable without production of the others.

 

[SIGNATURE PAGE FOLLOWS]

 

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement by their duly authorized representatives.

 

Integra Pharma Solutions LLC  
     
By:    
Print Name: Prashant Patel  
Title: Authorized Representative  
Date:    
     
SOSRx LLC:  
     
By:    
Print Name: Surendra Ajjarapu  
Title: Authorized Representative  
Date:  

 

 

 

 

 

Exhibit 10.3

 

MEMBER ASSET CONTRIBUTION AGREEMENT

 

THIS ASSET CONTRIBUTION AGREEMENT (this “Agreement”), is made this 15th day of February, 2022 by and between Exchange Health, LLC, a Michigan limited liability company (“Member”) and SOSRx LLC, a Delaware limited liability company (“Company”). The Company and the Member shall be individually referred to herein as a “Party” and collectively referred to herein as the “Parties.

 

RECITALS

 

WHEREAS Member is engaged in the pharmacy services and pharmaceutical distribution business in the United States (the “Business”);

 

WHEREAS Company shall be a joint venture in the pharmacy services and pharmaceutical distribution business with Member and TRxADE HEALTH, INC., a Delaware corporation, as the other member, pursuant to the Operating Agreement (described below);

 

WHEREAS Member desires to contribute to the Company certain assets and assign certain contracts as set forth herein in consideration of Company admitting Member as a member of Company pursuant to the terms and conditions as set forth in the operating agreement attached as Exhibit A (the “Operating Agreement”); and

 

NOW, THEREFORE, in consideration of the premises and the respective warranties, representations, covenants and agreements hereinafter set forth, Member and Company hereby mutually agree as follows:

 

1. Contributed Assets. Member agrees to sell, assign, transfer and deliver to Company, and Company agrees to purchase from Member, on the Closing Date (as defined in Section 4 hereof), all of the right, title and interest of Member in and to all of the following assets which are owned and/or used by Member in connection with the Business, free and clear of all security interests, liens, claims and other encumbrances:

 

(a) the specific assets listed on Schedule 1, attached hereto (collectively, the “Contributed Assets”); and

 

(b) other contracts (if any) set forth as Assumed Contracts and Permits (defined below) and contemplated in Schedule 3 attached hereto and made a part hereof.

 

The Contributed Assets shall not include, and Member shall retain, all other assets other than the Contributed Assets, including, but not limited to, cash, certificates of deposit, contracts (other than the Assumed Contracts), accounts receivable, Benefit Plans (collectively, the “Non-Assumed Assets”), fully listed and enumerated on Schedule 4 attached hereto.

 

 1 of 13
 

 

2. Contracts Assumed by Company. Company and Member agree that Company shall not assume, nor shall Company in any way be responsible for, any liability, obligation, claim or commitment, contingent, actual or otherwise, known or unknown, of Member or any of its shareholders, directors, principals, officers, employees or agents, it being expressly understood and agreed that Member shall continue to be responsible for any and all liabilities, obligations, claims or commitments of Member and the Business entered into on or prior to and after the Closing Date, including but not limited to, any sales, income, payroll or other taxes, employee Benefit Plans, obligations to other creditors including vendors, employees and customers or other liabilities, obligations, claims, any other claims or liabilities arising out of the operation of the Business prior to and after the Closing Date, or the ownership of the Contributed Assets prior to the Closing Date, or commitments of the Member incurred in connection with the transactions contemplated hereby. Notwithstanding the preceding sentence, Company agrees that it will, on the Closing Date, assume and agree to perform and discharge solely and only those specific obligations and commitments of Member set forth as leases, agreements and contracts and liabilities specifically set forth on Schedule 3 (the “Assumed Contracts”), and only to the extent that those obligations and commitments are incurred and arise after the Closing Date.

 

3. Purchase Price, Payment, and Liabilities.

 

(a) Purchase Price and Payment. The total purchase price (the “Purchase Price”) for the Contributed Assets shall be the membership interests and rights to held by Member described in the Operating Agreement, attached hereto as Exhibit A; and

 

(b) Liabilities.

 

(1) It is understood that the Company is not assuming any of Member’s liabilities or obligations other than the obligations and commitments of Member arising under the Assumed Contracts (and only as they are incurred after the Closing Date), and Member agrees to pay and discharge all of its other liabilities and obligations promptly as due and in due course.

 

(3) Member agrees to pay the cost of any sales, transfer or similar taxes payable in connection with the sale, assignment, and transfer of the Contributed Assets and the assumption of the Assumed Contracts. Any sales or use taxes imposed upon the operation of the Business prior to Closing Date shall be paid by Member and any such taxes imposed upon the operation of the Business on or after the Closing Date shall be paid by Company. Any personal property taxes imposed upon the Business with respect to tangible personal property included in the Contributed Assets shall be paid by the Member with respect to the period prior to and on the Closing Date.

 

4. Closing.

 

(a) The Closing (“Closing”) of the transfer of the Contributed Assets and the assumption of the Assumed Contracts shall take place upon the simultaneous execution of the Operating Agreement and this Agreement (the “Closing Date”).

 

(b) At the Closing, Member shall deliver to Company the following:

 

(1) such bill of sale or other good and sufficient instruments of assignment, transfer and conveyance as Company shall request, to convey and to transfer to Company all right, title and interest of Member in the Contributed Assets to Company, free and clear of all security interests, liens, claims and encumbrances;

 

(2) such other instrument or instruments of transfer, if any, as Company shall reasonably request to vest in the Company good and marketable title to the Contributed Assets;

 

(3) delivery of Required Consents (as defined in Section 7(b) hereof), fully executed by all parties;

 

 2 of 13
 

 

(4) all requisite resolutions or actions of the Member’s managers and members approving the execution and delivery of this Agreement and the consummation of the transaction contemplated herein.

 

(6) delivery of all other documents and instruments necessary to release and discharge all liens, claims, security interests and other encumbrances on all Contributed Assets.

 

(c) At the Closing, Company shall deliver to Member the following:

 

(1) the fully executed Operating Agreement; and

 

(2) the assumption agreement in the form attached hereto as Exhibit B, to assume the Assumed Contracts.

 

5. Representations, Warranties and Covenants

 

5.1 Of the Member. Member represents and warrants, and from and after this date, covenants to Company as follows:

 

(a) Organization and Authority. Member is a limited liability company, duly organized, validly existing, and in good standing under the laws of the State of Michigan and has all requisite corporate power and authority to carry on its business as it is presently being conducted, to enter into this Agreement, and to carry out and perform the transactions contemplated hereby. The execution, delivery and performance of this Agreement by Member has been duly authorized and approved by its members and its managers, and will not violate its organization documents, or any agreement to which it is a party or by which it is bound or any law, rule, regulation or court order. Member has delivered to Company true and complete copies of its organization documents.

 

(b) Absence of Conflicts. The execution and delivery by Member of this Agreement does not, and the completion of the transactions contemplated by this Agreement will not, result in any conflict with, breach of, or termination or forfeiture under (or upon the failure to give notice or the lapse of time, or both, result in any conflict with, breach of, or termination or forfeiture under) any terms or provisions of the charter documents, as amended, of Member or any statute, rule, regulation, judicial or governmental decree, order, judgment, agreement, lease, loan agreement, debenture, indenture, mortgage or other instrument to which Member is a party or to which any of its assets are subject and which individually or in the aggregate is material to Member.

 

(c) Enforceability. Upon the due execution and delivery by the parties, this Agreement, and all other instruments, documents and agreements to be delivered by Member in connection therewith, are the legal, valid and binding obligation enforceable against each of them in accordance with its, and their, terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally.

 

(d) Equity Investments. Member hereby certifies that it has no direct or indirect equity interest in any other corporation, partnership, joint venture or other entity.

 

(e) Compliance with Applicable Laws. Member has duly complied with all applicable laws, rules, regulations, ordinances, and all judgments, orders, rulings, and decrees of all federal, state and local governmental authorities (collectively, “Laws”).

 

 3 of 13
 

 

(f) Title and Solvency. Member has and will transfer to Company good and marketable title to the Contributed Assets. The Contributed Assets are free and clear of restrictions on or conditions to transfer or assignment. The Contributed Assets will be transferred to Company free and clear of mortgages, liabilities, obligations, security interests, liens, encumbrances, claims and restrictions, except for the Assumed Contracts. The Contributed Assets are not held under any leases, security agreements, conditional sales contracts, or other title retention arrangements. Except for the Non-Assumed Assets listed on Schedule 4, the Contributed Assets constitute all of the property now used in the Business and necessary for the conduct of the Business in the manner and to the extent presently conducted and operated, including all licenses necessary for the operation of the Business by the Company. As of and based on the financial condition of Member as of the Closing Date, after giving effect to the transactions contemplated hereby and the receipt by Member of the Purchase Price, the fair saleable value of Member’s remaining assets exceeds the amount that will be required to be paid on or in respect of Member’s debts and other liabilities (including known contingent liabilities) as they mature.

 

(g) Financial Statements. The unaudited financial statements of Member as of the year ended December 31, 2021, attached hereto as Schedule 5.1(g) (including balance sheets, income and cash flow statements) (the “Financial Statements”), fairly present the financial condition and results of operations of Member for the period then ended.

 

(h) No Liabilities. Member is not subject to any liability (including without limitation, unasserted claims whether know or contingent) whether absolute, contingent, accrued or otherwise, which is not shown or which is in excess of amounts shown or reserved for in the Financial Statements, other than those liabilities are specifically listed on Schedule 5.1(h) hereto.

 

(i) Taxes. Member has filed all income, franchise, employment, payroll, sales, use and other tax returns required to be filed by the Closing Date, has paid when due all taxes shown to be payable therein and has no tax liens or any pending or threatened assessment for taxes in addition to those payable therein. Company shall not become liable, as the result of the consummation of the transactions contemplated herein, for any tax liability of Member, or for any tax liability which relates to the Business or the Contributed Assets, under any federal, state, local or foreign income, excise, property, business, employment, occupation, sales, use or other taxes which accrued or arose on or prior to the Closing Date or which relate to any transaction that took place or event which occurred on or prior to the Closing Date.

 

(j) Litigation. There are no claims, actions, suits, arbitrations, criminal or civil investigations or proceedings pending or involving or, to the Knowledge of the Member threatened against the Member before or by any court or governmental or nongovernmental department, commission, board, bureau, agency or instrumentality, or any other person. To the Knowledge of the Member, there is no valid basis for any claim, action, suit, arbitration, investigation or proceeding that could reasonably be expected to be adverse to the business, assets, operations, prospects or condition (financial or other) of the Member before or by any person. There are no outstanding or unsatisfied judgments, orders, decrees or stipulations to which the Member is a party that involve the transactions contemplated herein or that would have a material adverse effect on the business, assets, operations, prospects or condition (financial or other) of the Member.

 

(k) Other Tangible Personal Property. Schedule 5.1(k), is a complete and accurate schedule describing and specifying the location of, all equipment, computers, phones, furniture, supplies, documentation, and all other tangible personal property owned by, or in possession of, or used by the Member in connection with the Business. The property listed in Schedule 5.1(k) constitutes all such tangible personal property necessary for the conduct by Member of the Business as now conducted. The tangible personal property and equipment of Member included in the Contributed Assets is in good operating condition and repair, ordinary wear and tear excepted.

 

(l) Trade Names, Trademarks, and Copyrights. Member owns, or holds adequate licenses or other rights to use, all trademarks, service marks, trade names, and copyrights necessary for the conduct of the Business. Member has not infringed, and is not now infringing, on any trade name, trademark, service mark, or copyright belonging to any other person, firm or corporation. Member is not a party to any license, agreement, or arrangement, whether as licensor, licensee, or otherwise, with respect to any trademarks, service marks, trade names or applications for them.

 

 4 of 13
 

 

(m) Trade Secrets and Patent Rights. Member has the right and authority to use such inventions, trade secrets, processes, models, designs, and formulas as are necessary to conduct the Business. Member is not a party to any license, agreement, or arrangement, whether as licensee, licensor, or otherwise, with respect to any patent, application for patent, invention, design, model, process, trade secret, or formula used or usable in the Business. The operation of the Business has not and will not violate or infringe on any patent or other proprietary right of any person, firm or corporation.

 

(n) Intellectual Property Rights. As used herein, “Software” means any object code, source code, binary code, executable code, and any documentation for the Internet and computer software applications and technology. “Intellectual Property Rights” means all intellectual property rights, including without limitation: (1) patents, patent applications, and patent disclosures, together with all reissuances, certificates, continuations, continuations-in-part, divisionals, extensions, registrations, and reexaminations thereof and all inventions, whether or not patentable and whether or not reduced to practice, (2) trademarks, service marks, trade dress, logos, trade names, websites, website pages and addresses, Internet domain names and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all certificates, applications, registrations, and renewals in connection therewith, (3) copyrightable works, copyrights, and all applications, registrations, renewals and moral rights (including any right to claim authorship to or to object to any distortion, mutilation, other modification or derogatory action in relation to a copyrightable work, whether or not such would be prejudicial to the author’s reputation, and any similar right, existing under common or statutory law, regardless of whether or not such right is denominated or generally referred to as a moral right) in connection therewith, (4) mask works and all applications, registrations, and renewals in connection therewith, (5) newsletters, magazines, books, handbooks, special reports, whitepapers videos, online education courses and membership programs currently offered by Member, seminars, conferences, classroom training programs and broadcast events offered by the Member, and (6) trade secrets, know-how and confidential business information (including ideas, research and development, inventions, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, discoveries, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans, proposals, and methods) owned or used or useful in connection therewith.

 

Member owns or possesses the entire right, title and interest in and to, or holds a license pursuant to an enforceable written agreement under, all Intellectual Property Rights contained with and/or necessary to use the Contributed Assets (including all Software) as currently used (collectively, the “Business Intellectual Property”). The Contributed Assets include all of the Intellectual Property Rights created, owned or held by Member or its respective affiliates that are used in the Business. All Business Intellectual Property has been and currently is subsisting, valid and enforceable and there has not been any act or omission by either Member or any of its respective affiliates that has had an adverse effect, or could have an adverse effect, on the validity or enforceability of any of Business Intellectual Property. The consummation of the transactions contemplated in this Agreement will not result in the loss or impairment of, nor require the consent of or payment to any other Person in respect of, Member’s rights to own, transfer, license or use any of the Business Intellectual Property, as owned or currently used by the Member.

 

None of the Business Intellectual Property, nor the content or use of the Contributed Assets violates, misappropriates or infringes, or otherwise conflicts with, the rights of another Person, including, without limitation, the Intellectual Property Rights of another Person. Member has not received any written or oral notice from any Person that the design, content, use, license or sale of the Contributed Assets or the Business Intellectual Property infringes or misappropriates the Intellectual Property Rights of any Person and to the Member’s Knowledge there are no bona fide grounds for such a claim. To the Member’s Knowledge, no other Person has infringed or misappropriated any part of or otherwise made any unauthorized use of the Business Intellectual Property.

 

 5 of 13
 

 

Schedule 5.1(n) contains a complete list of (i) all patents and pending patent applications; (ii) all trademarks, service marks and trade dress, including all registrations and applications; (iii) all copyrights, registered and unregistered; (iv) all domain name registrations and websites; (v) all Contracts to which a Member is a party or is otherwise obligated; and (vi) all written consents, settlements, judgments, injunctions, decrees, awards, stipulations, orders or similar litigation-related, or inter partes obligations to which any Member is a party or to which the Member is otherwise bound, and (vii) all Software, that are part of or relate to the Business Intellectual Property. Other than the Contracts identified in Schedule 5.1(n) Exclusions, pursuant to which Member has obtained a valid license from a third party, Member owns or possesses the entire right, title and interest in and to the Business Intellectual Property.

 

All Business Intellectual Property owned by Member Parties was developed solely by either (i) Member Owner individually, (ii) employees of a Member acting within the scope of his/her employment who have validly and irrevocably assigned to the Member all of his or her rights, including all Intellectual Property Rights therein or related thereto, or (iii) by third parties who have validly, irrevocably and exclusively assigned (or validly licensed, if not assignable) to the Member all of their rights, including to the extent assignable all Intellectual Property Rights therein or related thereto.

 

Member has taken industry standard best practices to protect the Business Intellectual Property, including, without limitation, its trade secrets, Source Code and databases. Member has not provided any confidential information related to the Business Intellectual Property to a third party except pursuant to written non-disclosure or other confidentiality agreements in a form reasonably sufficient to protect the Intellectual Property Rights embodied in such confidential information. Member is not under any contractual or other obligation to disclose to any third party any Business Intellectual Property. Member has not transferred ownership of, or granted any exclusive license with respect to, any Business Intellectual Property.

 

No Software contained in the Contributed Assets contains any computer program code authored, created, designed, developed or implemented by Member that incorporates, contains, references, interfaces with, uses, or links to, any Public Software in any manner that would require disclosure of the Software source code to the public. Schedule 5.1(n) Public Software includes a complete list of all Public Software or portion thereof that is in any way incorporated in, contained in, referenced by, interfaced with, used by, or linked to, by any Software in the Contributed Assets and an explanation of how such Public Software is used, and for Public Software that any Copyleft Public Software, an indication of whether the Public Software has been distributed or modified by or for Member. Member’s Knowledge, the Websites and Software contained in the Contributed Assets do not contain any computer code intentionally designed to disrupt, disable, or harm in any manner the operation of any software or hardware or to allow a third party to have access to the user’s computer or network without such user’s authority. None of the Software, or any portion thereof, contained in the Contributed Assets has been deposited or is obligated to be deposited pursuant to a source code escrow agreement or similar arrangement for the benefit of any Person, nor has Member made the Source Code, or any portion thereof, available to any Person. “Public Software” means any software that contains, includes, incorporates, or has instantiated therein, or is derived in any manner (in whole or in part) from, any software that is distributed as free software, open source software (e.g., Linux) or similar licensing or distribution models, including software licensed or distributed under any of the following licenses or distribution models, or licenses or distribution models similar to any of the following: (1) GNU’s General Public License (GPL) or Lesser/Library GPL (LGPL); (2) the Artistic License (e.g., PERL); (3) the Mozilla Public License; (4) the Netscape Public License; (5) the Sun Community Source License (SCSL); (6) the Sun Industry Standards License (SISL); (7) the BSD License; (8) the Apache License; and (9) the Affero General Public License. “Copyleft Public Software” means Public Software subject to a license that requires, as a condition of use, modification or distribution, that such Public Software, or modifications or derivative works thereof, be made available or distributed in source code form or be licensed for the purpose of preparing derivative works or distribution at no fee. Copyleft Public Software includes, without limitation, Public Software subject to the (v) GNU’s General Public License (GPL) or Lesser/Library GPL (LGPL); (w) the Mozilla Public License; (x) the Sun Industry Standards License (SISL); (y) the Affero General Public License; and (z) to the extent applied to software, all Creative Commons “sharealike” licenses.

 

 6 of 13
 

 

All data that has been collected, stored, maintained or otherwise used by or in connection with the Contributed Assets has been collected, stored, maintained and used in accordance with applicable laws and any applicable agreements in all material respects. Member has not received a notice of noncompliance with applicable data protection laws, rules, regulations, guidelines or industry standards, or any terms of service, terms of use or other agreements applicable to third party websites or data or the gathering or collection thereof. No government funding, facilities or resources of a university, college, other educational institution or research center or funding from third parties was used in the development of the Business Intellectual Property and no governmental body, university, college, other educational institution or research center has any claim or right in or to the Business Intellectual Property. Member is not a party to any outstanding indemnification agreements to indemnify any other Person against any charge of infringement.

 

To Member’s Knowledge, the Software included in the Contributed Assets will perform the functions that Member has represented to Company that it will perform, substantially as described. To the Knowledge of Member, the Software does not contain any “back door,” “time bomb,” “Trojan horse,” “worm,” “drop dead device,” “virus” (as these terms are commonly used in the computer software industry), or other software routines or hardware components intentionally designed to permit unauthorized access, to disable or erase software, hardware, or data, or to perform any other similar type of unauthorized activities.

 

Schedule 5.1(n) Persons sets forth a complete and accurate list of each Person that has, or was provided by the Member with, a copy of the Member’s source code, including the source code for the Software set forth on Schedule 5.1(n) Persons; all of such Persons have executed valid confidentiality agreements with respect to such source code, none of which confidentiality agreements, to the Knowledge of the Company, has been breached. No current or former partner, director, officer, or employee of the Company will, after giving effect to each of the transactions contemplated herein, own or retain any rights in or to, have the right to receive any royalty or other payment with respect to, any of the Intellectual Property used or owned by the Company

 

(o) Compliance With ERISA; Benefit Plans.

 

(i) Schedule 5.1(o) sets forth a list and brief description of all “employee pension benefit plans” (as defined in Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)), “employee welfare benefit plans” (as defined in Section 3(1) of ERISA), bonus, deferred compensation plans or arrangements, and other employee fringe benefit plans (all the foregoing being herein called “Benefit Plans”) maintained, or contributed to, by Member in connection with the Business for the benefit of any officers or employees as Member, whether of a legally binding nature or in the nature of informal understandings. Member has delivered to Company true, complete and correct summaries of (A) each Benefit Plan, (B) the most recent annual report on Form 5500 filed with the Internal Revenue Service with respect to any Benefit Plan (if any such report was required) and (C) each trust agreement and group annuity contract relating to any Benefit Plan.

 

(ii) Member is in compliance in all material respects with the provisions of ERISA and the regulations and published interpretations thereunder, no “reportable event” (as defined in Section 4043 of ERISA and the regulations thereunder) has occurred with respect to any Benefit Plan which is subject to the provisions of Title IV of ERISA and which is maintained for employees of Member or any of its Affiliates, and there are no unfunded vested liabilities under any such Benefit plan.

 

(p) No Defaults on Assumed Contracts. All leases, agreements and other contracts constituting the Assumed Contracts are valid and binding, enforceable, in full force and effect, are fully performed, and with no default or breach existing, or which would occur but for the existence of notice or the lapse of time. Member has provided Company complete and accurate written copies of all Assumed Contracts and any amendments thereto.

 

 7 of 13
 

 

(q) Contracts. Schedule 5.1(q) All Contracts, attached hereto, sets forth a complete and accurate list of all material agreements of the Member, written or oral (the “Contracts”), including without limitation, any (1) sales or adverting agreement or any agreement related to a commission; (2) any loan applications; (3) any contract for the future purchasers of products, materials, supplies, or services; (4) promissory note, loan agreement, or other agreement for the borrowing of money; and (5) non-competition agreement or similar agreement which restricts the Business from engaging in any aspect of its business in which it may engage. Member has provided Company complete and accurate copies of all written Contracts and summaries of all oral Contracts. Member has, in all material respects performed all the obligations required to be performed by it to date under the Contracts. Member is not in, or alleged to be in, material default under any of the Contracts, commitments, instruments, or obligations, and there exists no event, condition, or occurrence which, after notice of time, would constitute a material default by it of any Contract.

 

(r) Permits. Schedule 5.1(r), attached hereto, sets for all permits, certificates, licenses, consents, filings, sanctions, registrations, variances, exemptions, orders, authorizations and approvals Member holds, and has made all declarations and filings with, all governmental bodies for the operation of the Business as conducted in the past or as presently conducted including the sale, transport, export, import or shipment of any pharmaceutical materials (whether in tangible form or otherwise) to any jurisdiction (collectively, the “Permits”). No suspension or cancellation of any such governmental Permit is pending or, to the knowledge of any Member, threatened. Each such Permit is valid and in full force and effect, and Member is in compliance in all material respects with the terms of such Permits. All such Permits shall be validly assumed and transferred to Company at the Closing.

 

(s) Related Party Transactions. Except as set forth in Schedule 5.1(s), no Related Party (i) has borrowed money from or loaned money or equipment to Member or any Member Party that is currently outstanding or otherwise has any cause of action or claim against Member, (ii) has any direct or indirect ownership interest in any property or asset used or developed by or for Member in the conduct of the Business except through such Person’s ownership of Member Interests, (iii) has or has had any direct or indirect ownership interest in, or served as an officer, director, employee or consultant of, any company which is a present competitor, supplier or customer of the Business or (iv) is a party to any agreement or is engaged in any ongoing transaction with Member other than employment in the ordinary course of the Business. “Related Party” means (i) any owner of the Member, (ii) any manager, member, partner, shareholder, equityholder, director, or officer of the Member, (iv) any family member of any Member and (v) any Affiliate of any Member.

 

(t) Restrictions on Business Activities. Except as set forth in Schedule 5.1(t) Restrictions: (a) none of the Contracts imposes (i) any non-compete obligation; (ii) any non-solicitation obligation; (iii) any restriction on the ability of Company to purchase the Contributed Assets; (iv) any restrictions on the ability of Company to operate the Business in the manner in which the Business has been or is currently conducted by Member, nor any restriction on Member’s or, after the Closing, Company’s operation of the Business in any geographic area; (v) any “most favored nations” or similar obligation to offer terms included in or based on another contract; or (vi) any consent to assignment requirements other than as set forth in the Required Consents on Schedule 2 hereof and (b) Member is not subject to any rule or pending legislative or regulatory initiative, under which Member is, or after the Closing Company would be, restricted from selling, licensing or otherwise distributing any of its technology or products or from providing services to customers or potential customers or any class of customers, in any geographic area, during any period of time or in any segment of any market.

 

(u) Product and Service Warranties. Each product or service sold, licensed, distributed, delivered or offered by Member is in conformity with all applicable contractual commitments and all express warranties in all material respects, and Member has no liability (and, to the Knowledge of Member, there is no basis for any present or future claim against Member giving rise to any liability) for violations thereof or other damages in connection therewith. No product sold, licensed, distributed or delivered by Member is subject to any guaranty, warranty or other indemnity beyond the applicable standard terms and conditions of sale or lease, except for such guarantees, warranties and indemnities that are implied under applicable law and not disclaimable.

 

 8 of 13
 

 

(v) Full Disclosure. Neither this Agreement (including any Exhibit or Schedule hereto), nor any report, certificate or instrument furnished to Company in connection with the transactions contemplated in this Agreement or the Operating Agreement, when read together, contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein, not misleading. All information or documents concerning the Member supplied in writing to Company or their respective agents during the due diligence process was, when given, true and accurate and complete in all material respects and there is no fact or matter which has not been disclosed in writing which renders any such information or document untrue or misleading at the date of this Agreement. No Member has any Knowledge of any information or fact pertaining to Member or the Business, assets or properties that have not been disclosed in this Agreement, the Schedules and Exhibits hereto, except for any facts relating solely to general economic, business or political developments affecting the economy generally, that could reasonably be expected (with or without the passage of time or both) to result in a material adverse effect on Member, the Contributed Assets or the Business.

 

(w) Securities Representations.

 

(i) Member recognizes that the membership interests of the of the Company and any shares of common stock of TRxADE HEALTH, Inc. which may be contributed to the Company pursuant to the terms of the earnout set forth in the Operating Agreement (collectively, the “Securities”) have not been registered under the Securities Act of 1933, as amended (the “1933 Act,” or the “Act”), nor under the securities laws of any state and, therefore, cannot be resold unless the resale of the Securities is registered under the 1933 Act or unless an exemption from registration is available. Member/Company may not sell the Securities without registering them under the 1933 Act and any applicable state securities laws unless exemptions from such registration requirements are available with respect to any such sale. Neither Trxade Health/Company is under any obligation to register such Securities under the 1933 Act or under any state “Blue Sky” laws prior to or subsequent to their issuance;

  

(ii) Member is an “accredited investor” as such term is defined under Rule 501 of the Act;

 

(iii) Member has such knowledge and experience in financial and business matters such that Member is capable of evaluating the merits and risks of an investment in the Securities and of making an informed investment decision, and does not require a representative in evaluating the merits and risks of an investment in the Securities;

 

(iv) Member recognizes that an investment in the Securities is a speculative venture and that the total amount of consideration tendered in connection with the Securities is placed at the risk of the business and may be completely lost. The ownership of the Securities as an investment involves special risks;

 

(v) Member confirms and represents that it is able (i) to bear the economic risk of the Securities, (ii) to hold the Securities (to the extent acquired by the Member) for an indefinite period of time, and (iii) to afford a complete loss of the Securities. Member also represents that it has (i) adequate means of providing for its current needs and possible personal contingencies, and (ii) has no need for liquidity in the Securities;

 

(vi) Member has carefully considered and has, to the extent it believes such discussion necessary, discussed with its professional, legal, tax and financial advisors, the suitability of an investment in the Securities for its particular tax and financial situation and its advisers, if such advisors were deemed necessary, have determined that the Securities are a suitable investment for it;

 

(vii) Trxade Health/Company is under no obligation to register or seek an exemption under any federal and/or state securities acts for any sale or transfer of the Securities, and Member is solely responsible for determining the status, in its hands, of the Securities acquired (to the extent acquired by the Member) and the availability, if required, of exemptions from registration for purposes of sale or transfer of the Securities;

 

 9 of 13
 

 

(viii) The Member is acquiring the Securities (to the extent acquired) for its own account for long-term investment and not with a view toward resale, fractionalization or division, or distribution thereof, and it does not presently have any reason to anticipate any change in its circumstances, financial or otherwise, or particular occasion or event which would necessitate or require its sale or distribution of the Securities; and

 

(ix) Member understands and agrees that a legend has been or will be placed on any certificate(s) or other document(s) evidencing the Securities in substantially the following form:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED OR ANY STATE SECURITIES ACT. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS (I) THEY SHALL HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED AND ANY APPLICABLE STATE SECURITIES ACT, OR (II) THE CORPORATION SHALL HAVE BEEN FURNISHED WITH AN OPINION OF COUNSEL, SATISFACTORY TO COUNSEL FOR THE CORPORATION, THAT REGISTRATION IS NOT REQUIRED UNDER ANY SUCH ACTS.

 

6. Representations, Warranties and Covenants of Company. Company hereby represents and warrants, and from and after this date covenants to Company as follows:

 

(a) Organization and Authority. Company is a corporation, duly organized, validly existing, and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as it is presently being conducted, to enter into this Agreement, and to carry out and perform the transactions contemplated hereby. The execution, delivery and performance of this Agreement by Company has been duly authorized and approved by its Board of Directors, and will not violate its Articles of Incorporation, By-Laws, or any agreement to which it is a party or by which it is bound or any law, rule, regulation or court order.

 

(b) Absence of Conflicts. The execution and delivery by Company of this Agreement does not, and the completion of the transactions contemplated by this Agreement will not, result in any conflict with, breach of, or termination or forfeiture under (or upon the failure to give notice or the lapse of time, or both, result in any conflict with, breach of, or termination or forfeiture under) any terms or provisions of the charter documents, as amended, of Member or any statute, rule, regulation, judicial or governmental decree, order, judgment, agreement, lease, loan agreement, debenture, indenture, mortgage or other instrument to which Company is a party or to which any of its assets are subject and which individually or in the aggregate is material to Company.

 

(c) Enforceability. Upon the due execution and delivery by the Parties, this Agreement will be a binding obligation of Company enforceable against Company in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally.

 

7. Actions Prior to and after the Closing Date. The respective parties hereto covenant and agree to take the following actions:

 

(a) Consents and Approvals. Member shall promptly to obtain all consents and amendments from parties to the Assumed Contracts on Schedule 2 which require consent, together with estoppel letters from parties to material agreements (the “Required Consents”).

 

(b) Member’s Employees and Member’s Business. On and as of the Closing Date, Member will take all action necessary to terminate the employees of the Business and shall pay such employees all sums (whether payroll, bonus, severance, vacation or otherwise) due to them through the close of business on the Closing Date, and to further terminated Member’s Business (other this it’s operation through the Company as its successor).

 

(c) Payment of Liabilities. Member shall pay or otherwise satisfy in the ordinary course all of its liabilities and obligations prior the Closing Date. After the Closing Date, Member shall pay or make adequate provision for payment, in full, of all its liabilities and tax and all obligations other than the Assumed Contracts.

 

 10 of 13
 

 

(d) Cooperation. Member shall provide Company with such assistance as may be reasonably requested by them in connection with the preparation of any tax returns, or financial or accounting audit of Company which involve the Member, it’s business, the Contributed Assets, and/or the Assumed Contracts.

 

(e) Cease of Business Operations. Member shall cease all Business operations after the Closing Date, other than to receive consideration under this Agreement and Operating Agreement, and Member shall change its name to something unrelated to the Business.

 

8. Indemnification. Member hereby agrees to hold harmless and indemnify Company and all of the other members thereof (other than Member) from all claims, loss, damage, cost and expense (including attorney’s fees) (collectively “Indemnified Costs”) arising from or in connection with prosecuting, settling, investigating, or defending any breach by Member of the warranties, representations and covenants set forth in this Agreement, or pursuant to any third-party indemnification claim related thereto.

 

9. Survival of Provisions. The agreements, representations and warranties by Member under this Agreement shall survive the contribution of the Contributed Assets to Company and shall not be deemed to be merged into any document executed hereunder.

 

10. General Provisions.

 

(a) Notices. All notices and other communications hereunder shall be in writing. Notices shall be delivered personally, by registered or certified mail, or by commercial courier, return receipt requested. Notices shall be effective when delivered in this manner and will to be deemed given on the date the notice is delivered to the following address:

 

If to Member:

 

Exchange Health, LLC

45340 Hanford Rd, Canton, MI 48187

If to Company:

SOSRx, LLC

2420 Brunello Trace, Lutz, FL 33558

 

(b) Entire Agreement, Amendment. This Agreement together with all of the Exhibits, Schedules and other documents referred to herein constitutes the entire Agreement between the parties with reference to the subject matter hereof and supersedes all prior agreements and understandings, whether written or oral, regarding the subject matter hereof, and may only be changed or modified in writing.

 

(c) Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware as applied to agreements made and performed in Delaware by residents of Delaware.

 

(d) Counterparts. This Agreement may be executed in counter parts, each of which shall be considered one and the same agreement.

 

(e) Specific Performance. The parties acknowledge that damages would be an inadequate remedy for any breach of the provisions of this Agreement and agree that the obligations of the parties hereunder shall be specifically enforceable.

 

 11 of 13
 

 

(f) Disputes. Any controversy or claim arising out of or relating to this Agreement, or the alleged breach thereof to shall be settled under the conflict resolution procedures of the Operating Agreement, incorporated herein by reference.

 

(g) Severability of Provisions. If any provision of this Agreement shall be held invalid or unenforceable, the remaining provisions of this Agreement shall not be affected thereby.

 

(h) Assignment, Successors and Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties and their respective successors and assigns. This Agreement may not be assigned by any party whether by operation of law or otherwise without the prior written consent of the other party.

 

(i) Third Parties. This Agreement is not intended, and shall not be construed, to confer upon any person other than the parties any rights or remedies, other than Trxade Health, Inc., a Delaware corporation, who as a member of the Company is a designated third party beneficiary. The headings contained in this Agreement are for reference only and shall not affect the meaning of any section.

 

(j) Fees, Costs and Expenses. Unless specifically stated to the contrary in this Agreement, all expenses incurred in connection with the transactions contemplated by this Agreement shall be the sole responsibility of the party incurring such expenses. Such expenses shall include fees incurred for accountants, investment bankers, brokers and legal counsel.

 

(k) Knowledge Defined. A Person will be deemed to have “Knowledge” of a particular fact or other matter if such Person is actually aware of such fact or matter, with an obligation to undertake a reasonable investigation in a reasonable amount of due diligence of such fact or matter. A Person (other than an individual) will be deemed to have “Knowledge” of a particular fact or other matter if any individual who is serving as a director, officer, partner, member, executor, or trustee of such Person (or in any similar capacity) has Knowledge of such fact or other matter.

 

(l) Person Defined. Any person, corporation, partnership, joint venture, association, organization, other entity or governmental or regulatory authority.

 

[Signature page follows]

 

 12 of 13
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement, as of the date and year first above written.

 

COMPANY: SOSRx, LLC.  
     
By:    
  Suren Ajjarapu, Authorized Manager  
     
MEMBER: Exchange Health, LLC  
     
By:    
  Hem Pandya, President  

 

 13 of 13

 

 

Exhibit 99.1

 

 

 

TRxADE Health forms joint venture SOSRx.com to Expand Medication Accessibility via Manufacturer Partnerships

 

TAMPA, FL, February 15, 2022 TRxADE HEALTH, INC. (NASDAQ:MEDS) (“TRxADE” or the “Company”), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced the formation with Exchange Health, LLC, of a joint venture, SOSRx, LLC (“SOSRx”), a Pharmaceutical Platform. SOSRx will provide pharmaceutical manufacturers a single platform to optimize the sale and distribution of their inventory directly to large pharmaceutical buyers across multiple classes of trade. SOSRx opens the market to short dated, over stock and slow-moving pharmaceuticals that would otherwise be subject to destruction. TRxADE anticipates growth in 2022 as more progressive manufacturers are expected to address the public need for enhanced medication accessibility and reliable supply of cost-effective pharmaceuticals.

 

“We see significant synergy between SOSRx’s innovative platform that addresses the unmet needs of big pharma and TRxADE’s rapidly growing network comprised of 12,700+ members and the nation’s top pharmaceutical supply houses”, said Prashant Patel Rph, President, TRxADE.

 

“This is a big win for healthcare providers and patients as TRxADE is now in a better position to make healthcare more readily accessible and affordable,” concluded Suren Ajjarapu, CEO, TRxADE.

 

“We believe that this partnership opens the supply chain to address the much larger needs of pharmaceutical companies as they begin to take future steps towards supply inefficiencies, accessibility and cost effectiveness of their pharmaceutical products while trying to safeguard the integrity of the nation’s distribution networks,” added Hem Pandya, Chairman, Exchange Health, LLC.

 

About TRxADE HEALTH, INC.

 

TRxADE HEALTH (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 12,700+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For info on TRxADE HEALTH, please visit the Company’s IR website at investors.trxadegroup.com.

 

 
 

 

Forward-Looking Statements

 

This press release may contain forward-looking statements, including information about management’s view of TRxADE’s future expectations, plans and prospects, within the meaning of the federal securities laws, including the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to the planned benefits, expected users of, and projected revenues of our joint venture with Exchange Health; our operations not being profitable; the commercial viability of new business lines, applications, products and technologies, and the costs of such items; the Company’s stock repurchase program; the adoption of the Company’s product offerings; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; challenges to the pharmaceutical supply chain posted by the COVID-19 pandemic and related matters; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; new competitors which may have more resources than we do; increases in direct to consumer sales of drugs; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and increased inflation and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; dilution which may be caused by future offerings; our ability to raise funding in the future, as and if needed, and the terms of such funding; increased inflation; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

 

Media Contact:

 

TRxADE HEALTH, INC.

media@trxade.com

 

SOURCE: TRxADE HEALTH, INC.